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ABSTRACT 
 
Annually, nearly 2000 patients are diagnosed with rectal cancer in Sweden. To date, the only known curative 
treatment is surgery and low anterior resection (LAR) is the operation of choice for tumours in the middle rectum. 
However, LAR has a high risk for short and long-term morbidity where one of the most severe complications is 
anastomotic leakage (AL). Since a diverting loop ileostomy has been shown to reduce the risk of early AL after 
LAR, nearly all patients in Sweden are currently diverted. Yet, a stoma, even temporary, is also associated with 
significant morbidity. Enhanced Recovery After Surgery (ERAS) is a perioperative care program with the aim to 
reduce surgical stress and thereby improve postoperative outcome after surgery. The aim of this thesis was to 
evaluate and optimise the treatment for patients with a diverting stoma following surgery for rectal cancer and to 
assess if compliance with ERAS influenced clinical outcome after primary diversion in LAR. 
In paper I, short-term morbidity after LAR in relation to a diverting stoma and ERAS was evaluated. All 287 
patients operated on for LAR at Ersta Hospital, Sweden, between 2002-2011, were included. Out of those, 139 had 
a diverting stoma (S+) at LAR and 148 patients had not (S-), whereas all were treated according to an ERAS 
program. Most of the diverted patients underwent surgery after 2007 due a change in practice at our institution. 
Data were prospectively collected in the ERAS database. Postoperative morbidity, including clinically apparent 
AL, was similar between the two groups, S+ and S-. Total rate of re-laparotomy was comparable but significantly 
more patients in the S- group underwent re-laparotomy due to AL. However, the total frequency of reinterventions 
due to AL did not differ. Postoperative recovery was faster among the patients in the S- group but this did not 
influence the length of stay.  
In paper II, long-term morbidity within 3 years after LAR depending on whether or not a diverting stoma was 
fashioned was evaluated. The cohort was the same as in paper I, but data regarding long-term morbidity and 
permanent stoma were retrospectively collected. Late AL, unexpected readmissions in the late postoperative course, 
rate of permanent stoma and oncological outcome were comparable between S+ and S-. AL was an independent 
predictor for a permanent stoma and patients in the S+ group had longer hospital stay during the 3 year follow up. 
In paper III, complications after closure of a loop ileostomy in relation to the type of anastomosis (hand-sewn or 
stapled) were analysed. The cohort consisted of 351 patients, operated on for stoma closure, 1999-2006, at three 
different Swedish hospitals. Data were collected retrospectively. In patients with a stapled anastomosis, the risk of 
small bowel obstruction after surgery was reduced by 50 percent, operation time was 10 minutes shorter and length 
of hospital stay was reduced by 1.5 day, compared with patients who received a hand-sewn anastomosis. 
In paper IV, a total of 29 patients, undergoing rectal cancer surgery between 2008-2013 at Ersta Hospital, were 
randomised either to oral nutritional supplements (ONS) and rectal enema before surgery or no preoperative 
nutritional intervention and mechanical bowel preparation with polyethylene glycol (PEG). Bowel cleansing, 
postoperative morbidity and patients’ nutritional and physiological status were assessed. The bowel was less clean 
in the right and mid colon but similar in the sigmoid and rectum in the ONS-group. In the interventional arm 
(ONS), patients gained in percent body fat, from randomisation to 3 days after surgery, and lost less in weight, from 
randomisation to 4 weeks after surgery, compared to the PEG-group. Postoperative morbidity did not differ. 
In conclusion, we did not find any benefit of a diverting stoma regarding short and long-term morbidity after LAR 
among patients treated within an ERAS program. However, there may be an increased risk of symptomatic 
anastomotic leakage requiring re-laparotomy in those patients who were not diverted. Nonetheless, overall 
complication rates were similar with and without diversion, which suggests that routine diversion for all patients, 
undergoing LAR in Sweden, may be called into question. Moreover, a stapled anastomosis during the closure 
procedure seems preferable, resulting in a reduced frequency of postoperative small bowel obstruction and 
shortening operative time. Finally, oral nutritional supplements and local rectal cleansing prior to rectal cancer 
surgery may be a safe alternative to traditional bowel cleansing and in addition improve patients’ nutritional status. 
Kajsa Anderin 
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THESIS AT A GLANCE 
 
 
 
 
PAPER 
 
AIM 
 
 
PATIENTS & 
METHODS 
 
 
RESULTS 
 
CONCLUSION 
 
I 
 
 
 
To assess short-term 
morbidity after LAR in 
relation to a diverting 
loop ileostomy and 
ERAS. 
 
 
Patients operated on for 
LAR (N=287), 
+/- diverting stoma and 
treated according to 
ERAS, Jan 2002-Dec 2011 
at Ersta Hospital. 
 
Prospective cohort 
comparing stoma (S+) and 
no stoma (S-) at LAR. 
 
Postoperative morbidity was 
53% vs. 43% (p 0.116), rate of 
AL 19% vs. 24% (p 0.316) and 
acute re-laparotomy 8% vs. 
15% (p 0.065) in S+ and S-, 
resp. In S+ 2% had acute 
relaparotomy due to AL, vs. 
14% in S- (p<0.001). 
Patients in S- had a faster 
postoperative recovery. 
 
A diverting loop 
ileostomy at LAR did 
not improve 
postoperative short-term 
morbidity but was 
associated with a 
delayed recovery 
compared to those 
without diversion. 
 
II 
 
 
 
 
To assess long-term 
morbidity (>30 days-3 
years) after LAR in 
relation to a diverting 
loop ileostomy. 
 
 
Patients operated on for 
LAR (N=287), 
+/- diverting stoma and 
treated according to 
ERAS, Jan 2002-Dec 2011 
at Ersta Hospital. 
 
Retrospective cohort 
comparing S+ and S- at 
LAR. 
 
Late AL (6% vs. 5%), late 
readmission (16% vs. 15%), 
permanent stoma (17% vs. 
14%) and oncological outcome 
(22% vs. 24%, over-all re-
currence) did not differ, S+ 
and S-, resp. 
LOS+ was 7 days in S+ vs. 4 
days in S- (p<0.001). 
 
A diverting loop 
ileostomy at LAR did 
not reduce long-term 
morbidity or 
oncological outcome 
but was associated with 
a longer total LOS 
compared to those 
without a stoma 
constructed at LAR. 
 
III 
 
To evaluate 
postoperative 
complications after 
closure of a diverting 
loop ileostomy in 
relation to type of 
anastomosis. 
 
Patients operated on for 
stoma closure (N=351), 
Oct 1999-Dec 2006, at 
Uppsala University 
Hospital, Karolinska 
University Hospital, 
Huddinge and Karlstad 
Hospital. 
 
Retrospective cohort, 
comparing hand-sewn 
(HS) and stapled (S) 
anastomosis at stoma 
closure. 
 
Total rate of AL was 3% and 
SBO was 13% (36% of those 
required re-operation). 
In the HS-group SBO was 
16% vs. 8% in S. 
In the S-group the risk of SBO 
was decreased by 56% (OR 
0.44, 95%CI 0.21-0.93), 
operation time 10 minutes 
shorter (p 0.015) and LOS 4 
days vs. 5.5 days in the HS-
group  
(p<0.001). 
 
A stapled anastomosis 
after closure of a 
diverting loop ileostomy 
was associated with 
decreased operation 
time, lower rate of 
postoperative SBO and 
shorter LOS compared 
to a hand-sewn 
anastomosis. 
 
IV 
 
 
 
 
To evaluate if bowel 
preparation can be safely 
achieved by oral 
nutritional supplements 
(ONS) and if this 
regimen affect 
postoperative morbidity, 
nutritional and 
physiological status in 
patients operated on for 
rectal cancer. 
 
 
Patients planned for rectal 
cancer surgery (N=29), 
between June 2008- Feb 
2013, were randomised to 
ONS or MBP with 
polyethylene glycol 
(PEG). 
 
Randomised controlled 
trial comparing ONS and 
PEG before rectal cancer 
surgery. 
 
In ONS 77% reached their 
recommended daily intake 
(RDI) before surgery, vs. 19% 
in PEG (p 0.003). 
The bowel was less clean in 
right and mid-colon but similar 
in sigmoid and rectum after 
ONS. Weight loss was -1.6 kg 
in ONS and -4.6 kg, in PEG, 
from randomisation to 4 weeks 
after surgery. 
 
ONS prior to rectal 
cancer surgery may be a 
safe alternative to 
traditional bowel 
cleansing. In addition, 
patients in the ONS-
group gained in 
nutritional status and 
lost less in weight 
compared to patients 
treated with PEG. 
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INTRODUCTION & BACKGROUND 
 
 
This thesis, “Aspects of diverting stoma and ERAS in rectal cancer surgery”, examines 
morbidity after low anterior resection in relation to a diverting stoma and the use of ERAS in 
rectal cancer surgery. In this section, background to the main topics - rectal cancer, diverting 
stoma and ERAS - will be presented.  
 
RECTAL CANCER 
 
Epidemiology 
Worldwide perspective 
With an incidence of 1 361 000 new cases every year, colorectal cancer (CRC) is the third most 
common malignancy worldwide, whereas rectal cancer
1
 constitutes approximately one third of 
cases.  
The incidence varies 10-fold across the world and the highest numbers are seen in Australia and 
New Zealand (incidence rate 45 and 32/100 000 inhabitants, men and women, respectively) and 
the lowest are found in the Western Africa (incidence rate 5 and 4/100 000 inhabitants, men and 
women, respectively).
1
 For unknown reasons, the prevalence of the disease is higher in men 
than in women. 
Globally, overall mortality is decreasing slightly
1
 and is clearly correlated to the stage of the 
tumour - the more advanced stage, the poorer survival. 
 
National perspective 
In Sweden, rectal cancer is the seventh most common cancer form and the median age at 
diagnosis is 72 years.
2
 Between 2009-2013, 2147 new patients/year were diagnosed, 1234 men 
(57%) and 913 women.
3
 The incidence has been relatively stable over the last decade with a 
tendency to increase, please see Figure 1. 
Since 1970 the mortality has decreased slightly but has been unchanged over the past ten years, 
see Figure 2.
2
 The 5-year relative survival in patients diagnosed between 2005-2009 was 61% 
in men and 64% in women, shown in Figure 3.
2
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Figure 1. Age standardised incidence in 
rectal cancer per 100 000 inhabitants, 
Sweden, 1970-2010. Men, Women.
2
  
 
Figure 2. Age standardised mortality in 
rectal cancer per 100 000 inhabitants, 
Sweden, 1997-2010. Men, Women.
2
 
 
Figure 3. Five-year relative survival in  
rectal cancer, Sweden, 1964-2003.  
Men, Women.
2
 
 
 
 
 
 
 
 
Figure 1-3 published with the permission from the Swedish rectal cancer registry. 
 
Several factors over the last decades have contributed to the improved prognosis. 
Implementation of the total mesorectal excision (TME), a new surgical technique, has reduced 
local and overall recurrence and improved cancer-specific survival.
4, 5
 Neoadjuvant 
radiotherapy (RT) in combination with TME has reduced local recurrence further and increased 
overall survival in radically resected stage III-tumours.
6
 Moreover, neoadjuvant RT alone has 
been shown to reduce local recurrence
7, 8
 and improve overall as well as cancer-specific 
survival.
8
 Furthermore, RT in combination with chemotherapy decreases the frequency of local 
recurrence.
9
 
% 
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Aetiology 
Nearly all CRC is believed to arise from an intestinal adenoma through an accumulation of 
mutations called the adenoma-carcinoma sequence.
10, 11
 The prevalence of adenomas, in a 
Swedish population, is around 10% and is higher in the elderly.
12
 Accordingly, most of the 
adenomas do not proceed into CRC. 
The mechanism behind the development of CRC is considered to be multifactorial. Lifestyle 
and environmental factors such as red meat,
13
 low intake of fruits and vegetables,
14
 physical 
inactivity,
15
 obesity,
15
 tobacco and alcohol use,
16, 17
 diabetes,
18
 male gender and increasing age
2
 
have been suggested to be involved.  
Patients with inflammatory bowel disease (Ulcerative colitis and Chrons’ disease) have a two to 
six times increased risk to develop CRC.
19
 The duration, severity and extent of the disease as 
well as co-existing primary sclerosing cholangitis and a family history of CRC are confirmed 
significant risk factors in this group of patients.
19, 20
 
Approximately 20% of all CRC is believed to have an underlying genetic factor, whereas two to 
four percent is monogenetic.
2
 Syndromes described are Lynch syndrome (known as hereditary 
non-polyposis CRC (HNPCC) which accounts for 2-5% of all cases),
2, 21
 familial adenomatous 
polyposis (characterised by development of hundreds to thousands of polyps in the 
gastrointestinal tract, mostly in duodenum, colon and rectum),
2, 21
 MUTYH associated 
polyposis
2
 and juvenile polyposis syndrome (JPS).
22
 
 
TNM-classification and Staging 
In 1932 the British pathologist Cuthbert Dukes presented a classification for colorectal cancer
21
 
severity, the so-called Dukes classification. This is divided into Dukes A, B and C. Dukes A 
represents invasion of the tumour into but not through the bowel wall, B invasion through the 
bowel wall but without affected lymph nodes and C, which includes affected lymph nodes. 
Later on Dukes D was added representing the presence of distant metastases.
21
 
Over the years, there have been several different classification and staging systems, in addition 
to Dukes, for colorectal cancer. The most commonly accepted, currently used in Sweden, is the 
Tumour, Nodes and Metastasis (TNM) classification developed by the American Joint 
Committee on Cancer (AJCC) in collaboration with the Union Internationale Contre le Cancer 
(UICC). The first edition was presented in 1977
23
 but the classification is revised every five 
years and has currently reached its seventh edition, in use since 2010.
24
 
The TNM-classification is used both prior to surgery (by radiological and clinic examination, 
prefix “c” for clinical classification) and postoperatively (based on the pathological specimen, 
prefix “p” for pathological classification). It gives an indication of prognosis, aids the planning 
of treatment (neoadjuvant, surgical procedure, adjuvant), assesses treatment efficacy and aids 
comparing and exchanging information of treatment between different centres. It also 
determines entry into clinical trials and contributes to the research into CRC.
25
 
Kajsa Anderin 
 
20 
 
Primary tumour (T), Regional lymph nodes (N) and Distant metastasis (M) 
The T-stage represents the depth of invasion of the primary tumour into the bowel wall – Tx 
(primary tumour cannot be evaluated), Tis (carcinoma in situ), T0-T4. 
Regional lymph nodes, affected or not, and the number of affected lymph nodes is described by 
the N-stage. This stage also includes tumour deposits (N1c). 
The M-stage represents the occurrence of distant metastasis, confined to one or several organs. 
The AJCC has also developed a staging system, according the different TNM-stages, where the 
stage, divided I-IV, correlates with the prognosis and is compared with the previous described 
Dukes classification. 
 
Surgery 
Until today, surgery is the only known curative treatment for rectal cancer. Various surgical 
approaches might be chosen depending on factors such as location of the tumour (upper, middle 
or lower part of the rectum), stage and growth of the tumour, patient co-morbidity and 
functional status. 
 
Total mesorectal excision 
In 1982, Heald et al presented the TME procedure for rectal cancer
26
 and a new era of rectal 
cancer surgery began. Previously reported five-year local (14-25%) and overall (42-63%) 
recurrence rates decreased to five and 22%, respectively
4
 and the five-year cancer-specific 
survival improved from 66 to 77% with the new technique.
5
 In addition, this sphincter-
preserving operation halved the frequency of permanent stomas.
5
 Hence, the principles of the 
TME procedure are now standard in rectal cancer surgery. 
In TME, mobilisation of the rectum and its associated mesorectum is performed with sharp 
dissection under direct vision along pre-existing embryological planes. The visceral fascia, 
enclosing the mesorectum, is divided from the pelvic parietal fascia and kept intact down to the 
pelvic floor. The hypogastric nerves are identified and preserved and the inferior mesenteric 
artery (IMA) is ligated approximately one centimeter from the aorta to ensure lymphatic 
clearance of upward spread in the mesocolon.
26
  
 
Anterior resection 
In Sweden, anterior resection (AR) is used in approximately 65% of all operations for tumours 
in the middle and upper rectum.
2
 
The term anterior resection is imprecise in the literature. It includes both High anterior 
resection/Partial mesorectal excision (PME), for tumours in the upper rectum and Low anterior 
   Introduction & Background 
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resection (LAR) for lower tumours. Moreover, in some publications, even the sphincter-
preserving surgical procedure performed before the introduction of TME is included. 
In LAR, a complete TME is performed, down to the pelvic floor with an intact mesorectum. 
After the rectal excision the colorectal/anal anastomosis, often situated approximately four to 
five centimetres above the anal verge, is created using a double stapling technique.
27
 More 
seldom, the anastomosis is hand-sewn by a trans-anal approach. 
The stapled anastomosis can be constructed as a straight anastomosis or a neoreservoir, 
including a colonic J-pouch, end-to-side anastomosis or a transverse coloplasty. A neoreservoir 
has been shown to improve functional outcome compared to a straight anastomosis,
28-32
 where 
an end-to-side construction is superior in that it is easier to perform, decreases operation time 
and lessens the number of staples lines used.
29
 The functional outcome between the different 
types of neoreservoir is similar.
28, 31, 33, 28, 34
 Compared with the colonic J-pouch and end-to-side 
anastomosis, transverse coloplasty is associated with an increase in anastomotic leakage (AL) 
which has led to a reduction in its usage in rectal cancer surgery.
29, 34
  
Regardless of the type of neoreservoir, a low anastomosis in the lesser pelvis is associated with 
a higher risk of AL.
35, 36
 Due to this, a temporary diverting loop ileostomy has been suggested to 
protect the anastomosis and to attenuate the severity of septic complications from a leakage.
35-40
  
Since distal spread in the mesorectum is rarely seen more than 2 cm below the distal margin of 
the tumour,
41
 high AR/PME has been advocated for tumours in the recto-sigmoid junction and 
upper part of the rectum.
42
 
PME is performed using the same principle as in TME surgery except for a transection of the 
mesorectum four to five centimetres below the distal part of the tumour. It has been shown that 
this technique results in a reduction in operation time, reduced incidence of AL, shorter length 
of hospital stay and a lesser need for diverting stoma compared with LAR, without 
compromising oncological outcome.
42
 
 
Abdominoperineal excision and Extralevator abdominoperineal excision 
Before the implementation of TME surgery, abdominoperineal excision, APE, was the golden 
standard for tumours in the middle and lower rectum.
42, 43
 Today, APE is considered for low 
rectal cancer, zero to five centimetres above the anal verge, when sphincter-preserving surgery 
cannot ensure distal margin. Moreover, it may be suitable for selected cases to avoid poor bowel 
function after surgery or when patients are not assumed to be able to manage an AL. 
In Sweden, approximately 90% of all patients with a tumour in the lower rectum undergo APE.
2
 
However, APE has a higher risk for local recurrence and poorer five-year overall survival 
compared to LAR,
44
 mainly due to an increased risk for intraoperative bowel perforation and 
involved CRM+ combined with this procedure.
43, 44
 
In APE, the principles of TME are used during the abdominal part of the surgery but instead of 
an intestinal anastomosis, a permanent colostomy is constructed. The specimen, along with the 
anal canal and the anus, is then removed through a perineal approach. This may create a waist 
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of the specimen in the junction between the rectum and the anal canal, close to the rectal muscle 
tube.
45, 46
 
In an attempt to improve oncological outcome, a modified APE, extralevator APE (ELAPE), 
has been introduced.
45
 In ELAPE, the abdominal part follows the same general approach as in 
APE but the intraabdominal dissection is ended when the levator ani muscles are reached.
45
 The 
specimen is then removed together with the levator muscles en bloc, resulting in a more 
cylindrical specimen compared to the ‘waisted’ specimen commonly occurring as a result of 
traditional APE.
45
 
In a recently published meta-analysis comparing ELAPE and APE, the former procedure was 
associated with a lower rate of intraoperative bowel perforations, involved CRM+ and local 
recurrence compared to APE while operation time, LOS and postoperative complications 
remained similar.
46
 
 
Hartmann’s procedure 
For tumours in the upper rectum where restoration of bowel continuity is not feasible, 
Hartmann’s procedure is an option. The principles are the same as for PME but instead of a 
colorectal anastomosis, an end colostomy is created and the remaining rectal stump is closed.
21
  
In Sweden, Hartmann’s procedure is used in approximately 10% of cases.2 It is often performed 
on patients with high co-morbidity, poor bowel function and/or other factors increasing the risk 
of AL.
21
 
  
Local excision 
The implementation of national screening programmes for CRC has led to an increased 
detection of stage I tumours.
47
 For early rectal cancer, i.e. T1-tumours where the risk for nodal 
metastasis is low, local excision (LE) can be an option.
21, 48
 Moreover, it can be considered in 
the palliative setting or when conventional surgery leads to a high risk of mortality or 
morbidity.  
LE can be performed either by transanal excision, transanal endoscopic microsurgery (TEM) or 
endoscopic sub mucosal dissection (ESD). The major advantages, compared to abdominal 
surgery, are the reduced surgical trauma with lower morbidity, faster postoperative recovery 
and shorter LOS.
48
 The limitations are the increased risks of local and overall recurrence when 
comparing with TME for T1-tumours.
48, 49
 Hence, further research into long-term results and 
preferably randomised trials to determine the efficacy of LE compared to abdominal surgery are 
needed. 
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Laparoscopy and robotic surgery 
Laparoscopic surgery for rectal cancer has become increasingly popular and has gained 
acceptance worldwide as studies have shown that it is associated with improved postoperative 
recovery, decreased LOS, peroperative bleeding and wound infection compared with open 
surgery.
50-55
 
Still, for tumours in the middle and lower rectum, i.e. when a complete TME should be 
performed, there has been doubt regarding oncological safety after laparoscopic surgery.
56-58
 
Laparoscopic LAR is considered technically challenging to perform with a long learning curve. 
Conversion rate to open surgery is high, varying between 0 to 34 percent
57, 59
 and those 
converted have been found to have a worse oncological outcome and increased postoperative 
morbidity.
57
 Operating in a deep and narrow pelvis may lead to difficulties in adequate 
exposure, the retraction needed can cause rupture of the mesorectal fascia and an incorrect 
identification of the distal resection margin. Moreover, the currently available laparoscopic 
stapling devices give a suboptimal angle when the distal part of the specimen is removed. 
Recently published data, including a Cochrane review,
54
 meta-analysis
55
 and three and five-year 
follow-up from two large RCT’s,51, 52 have concluded that cancer-specific and overall survival 
as well as local and distant recurrences are similar between open and laparoscopic surgery for 
rectal cancer. Moreover, the frequency of CRM+ and number of resected lymph nodes are 
equal. Hence, in the three-year follow-up from the COLOR II-trial,
51
 where patients with T3-T4 
tumours with threatened CRM were excluded, it should be noted that for tumours in the middle 
rectum, local recurrence rates were higher in the laparoscopic group (6.5% vs. 2.4%) while for 
low tumours the recurrence rate was lower in the laparoscopic group (4.4% vs. 11.7%).  
In an attempt to improve oncological outcome for those tumours suitable for LAR, a new 
laparoscopic procedure is under development, transanal TME (Ta TME). To facilitate the 
dissection of the most distal part of the rectum this mobilisation is performed by a transanal 
approach in a minimal invasive fashion. The laparoscopic abdominal part can be performed 
simultaneously, enhancing the operation for both teams by providing traction and counter 
traction and by guiding each other to the correct dissection plane.
59, 60
 The specimen is removed 
trans-anally and the anastomosis can either be stapled or hand-sewn. The potential benefits of 
this procedure regarding oncological outcome and anorectal function are still unclear. Currently, 
there is an on-going international multicentre RCT comparing Ta TME with laparoscopic TME 
surgery for mid and low rectal cancer, the COLOR III-trial.
61
 
As technology continues to advance, robotic surgery has become the next step in minimally 
invasive rectal cancer surgery. In addition to the improved short-term outcome with 
laparoscopy, robotic surgery gives a stable three-dimensional view, reduces surgeon tremor, 
increases the range of movement of instruments and improves surgeon ergonomics.
62
 The 
technique has been suggested to be superior for surgery in the lesser pelvis, especially in obese 
men and it may also improve urogenital functions due to less damage to the autonomic plexus 
and has a lower conversion rate
63
 compared with traditional laparoscopic surgery. Nonetheless, 
there has not been any robust evidence in favour of robotic surgery compared to laparoscopy 
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regarding short-term outcome.
62, 63
 Moreover, long-term outcome, including oncological results, 
is still unknown.
63
 
Both robotic and laparoscopic surgery has a longer operation time and increased costs 
compared to open surgery.
50, 54, 55, 57, 63
 
 
Diverting stoma in rectal cancer surgery 
The earliest stomas, (Gr. Mouth or opening) were unintentional enterocutaneous fistulas from 
penetrating abdominal injuries or complications of intestinal diseases such as diverticulitis or 
incarcerated hernias.
64
 In the 16
th 
and 17
th
 centuries the first surgical stomas were described.
21
 
The series were small and patients died in the early postoperative period. It was not until 1793 
that Duret, a French military surgeon, constructed the first successful stoma - a colostomy on a 
3-year old infant with anal atresia. The patient lived until 45 years of age.
64
 
Abdominal trauma, bowel obstruction and anal atresia were treated by loop colostomies and 
later on, in the late 19
th
, end stomas were constructed. End colostomies became popular through 
the introduction of Hartmann’s procedure in the early 20th century. Subsequently, end 
ileostomies were first described by the German surgeon Baum in 1879, and were used in the 
treatment of ulcerative colitis.
64
  
In 1961, Turnbull described the first loop ileostomy for patients with a short or fat mesentery or 
in the obese patient where the blood supply of an end stoma might become compromised.
21
 The 
distal end of the ileum was closed and a loop of the proximal ileum was constructed. Later on, 
in 1974, Alexander-William realised that a loop ileostomy could be constructed as a temporary 
solution.
21
 
Currently, the indications for faecal diversion, either through an ileostomy or a colostomy, 
include surgery for CRC, IBD, diverticulitis, trauma, pelvic sepsis, ischemic bowel, faecal 
incontinence, fistulae, obstetric complications, paediatric intestinal malformations and bowel 
obstruction.
64
 
The stoma can be temporary or permanent and constructed as an end or loop stoma (Figure 4 
and 5). Compared with an end stoma, a loop stoma is often easier to close, preferable at the 
stoma site without the need for laparotomy, and it also creates a diversion for the distal limb in 
cases of obstruction of the bowel distal to the stoma. 
After introduction of the first successful stomas, postoperative care was hampered by the lack of 
appropriate stoma appliances, causing serious skin complications and serositis from the liquid 
content of the ileum. The serosal damage led to stricture formation and bowel obstruction at the 
stoma site. In 1952, Brooke developed a new method of suturing the intestinal mucosa to the 
skin, reducing the rate of these complications.
21
 In addition, the introduction of enterostomal 
therapists (ET), specially trained stoma nurses, and specialised stoma appliances for correct 
bandaging of the stoma improved the results and care of the stoma furthe
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Enterostomal therapists 
The ET plays a central role in the care of the stoma patient. Preoperatively, in the elective 
setting, the ET educates, informs and helps patients to overcome the fear associated with the 
procedure and also marks a proper site for stoma creation, taking into consideration patient 
ergonomics. Marking of the site is done in the upright position, preferably in the left or right 
lower quadrant at the peak of the infraumbilical fat mound. One should avoid placing the stoma 
close to a bony prominence, the waistline, a scar, the umbilicus, the groin or skinfolds, which 
may all interfere with appliance management. For obese patients or those in wheelchairs, 
placing the stoma in one of the upper quadrants may be superior.
64
 
Suboptimal stoma location can cause difficulties with stoma handling and appliances, which 
can result in leakage and skin irritation thereby increasing patient discomfort and 
embarrassment. Therefore, the correct marking is essential.  
Patient education and training starts as soon as possible postoperatively.  This includes stoma 
bandaging, emptying the pouch and caring for the parastomal skin. After discharge, follow-up 
by the ET is mandatory for further help with appliance and any stoma-related complications.
64
 
 
Indications 
In rectal cancer surgery, a permanent end colostomy is performed in APE and Hartmann’s 
procedure (the latter one can, if possible, be reversed later on). In LAR, the majority of the 
patients are currently diverted either with a loop ileostomy or a loop transverse colostomy. 
When there are risk factors for AL such as patient co-morbidity, low serum albumin, steroid use 
or peroperative difficulties, a diverting loop ileostomy can be used even following a high 
AR/PME. 
In case of intestinal obstruction due to the tumour, a diverting stoma can be constructed in the 
emergency setting, prior to definitive surgery. This loop stoma should be placed as distally as 
possible, without interfering with the tumour area. Hence, both loop ileostomy and loop 
colostomy can be an option. 
Moreover, if not constructed at primary surgery, a diverting stoma can be used in both 
emergency and elective treatment for AL as well as in the palliative setting. 
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Figure 4. End stoma                  
 
Figure 5. Loop stoma
 
Loop ileostomy 
In Sweden and the United Kingdom, nearly all patients undergoing LAR are diverted by a loop 
stoma
2, 65
 in an attempt to protect the low anastomosis. Except for rectal cancer surgery, a loop 
ileostomy is most often used in IBD surgery after proctocolectomy with ileal-pouch anal 
anastomosis. 
Many surgeons consider loop ileostomy as the preferred diversion in LAR, instead of a loop 
transverse colostomy. A loop ileostomy is considered to have less bulky content and less odour, 
requiring fewer appliance changes and is easier to perform compared to a loop transverse 
colostomy.
64
 Moreover, the risk of stoma prolapse and parastomal hernias is reduced and after 
stoma closure, postoperative complications such as wound infections and incisional hernias are 
decreased in favour of loop ileostomy.
21, 66
 A Cochrane review, comparing the two types of 
stomas for faecal diversion of colorectal anastomosis, showed a lower frequency of stoma 
prolapse among loop ileostomies but with regards to other outcome measures, larger RCT are 
warranted to clarify which stoma is preferable in LAR.
67
   
 
Construction and closure 
At the preoperatively marked stoma site, a trephine is made by excision of skin and 
subcutaneous tissue. When reaching the anterior rectus sheath, a cruciate incision is performed 
and the muscles are split longitudinally. The posterior fascia is opened and a loop of the 
terminal part of the ileum, as close to the ileocaecal valve as possible, is delivered through the 
abdominal wall without tension. The trephine in the abdominal wall should be straight and 
admit two fingers. The ileum can either be rotated so that the afferent limb is placed caudally or 
left without rotation and a rod or a catheter can be used to support the loop. However, most 
important is to remember the orientation of the loop when closing the abdominal wall.  
   Introduction & Background 
27 
 
Once the abdominal wall is closed, a transverse incision is made in the distal to the middle part 
of the intestinal limb, at the antemesenteric border. The afferent and the efferent limbs are 
everted and sutured with absorbable interrupted mucocutaneous sutures, and when possible 
including the serosa at the antemesenteric portion. 
64
 Depending on type of primary procedure, 
the stoma can be constructed by laparotomy or laparoscopy 
21, 64
. 
Closure of the loop ileostomy is usually performed within 3-6 months after creation, when the 
patient has recovered, the inflammation and oedema in the abdomen and surrounding the stoma 
has resolved and the adhesions are less fibrotic.
64,
 
68
 Time between construction and closure 
vary, depending on the reason for construction, postoperative complications, co-morbidity and 
adjuvant therapy.
64
 The closure procedure is not high-priority and may be postponed. 
Before closure, a rectal examination, including both rectoscopy and CT with rectal enema, 
should be performed to ensure integrity of the anastomosis and to exclude stenosis or recurrence 
of the disease.  
A peristomal skin incision is made and the serosa of the two limbs is freed from the sub-
cutaneous fat, the rectus sheath and the peritoneum. The ileum must be completely freed so that 
it easily can be replaced into the peritoneal cavity. Normally, this procedure can be done at the 
stoma site, but in three to five percent, due to severe adhesions, a laparotomy may be necessary. 
68, 69
The new anastomosis is created in a hand-sewn or stapled fashion. If hand-sewn, the everted 
limbs of the ileum are turned back, eventually skin edges are excised and the opening in the 
ileum is sewn with a seromuscular continuous suture (Figure 6). If the limbs are affected or 
perforated during the closure procedure, a short small bowel resection is performed before the 
end-to-end anastomosis is constructed. 
Using a linear staple, a stapled side-to-side anastomosis is created by putting the staple advices 
through the two bowel openings or by creating an incision just below the open edges. 
Thereafter, a linear staple is used, below the bowel openings, to close the remaining enterotomy 
(Figure 7). The enterotomy can also be closed in a hand-sewn manner.  
After the construction of the anastomosis, the bowel is inserted back in the peritoneal cavity and 
the fascia is closed. The skin is most often left partially open with the use of a subcuticular 
purse-string suture, since this has been shown to decrease the frequency of wound infections 
compared with primary closure.
64
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Hand sewn versus stapled anastomosis 
Currently, there is no consensus regarding the best surgical technique for closure of a loop 
ileostomy. Surgeon preference and local practice dictate the choice of anastomosis constructed.  
It has been suggested that a stapled anastomosis creates a larger intestinal lumen and forces the 
surgeon to free the ileum more extensively in the peritoneal cavity in order to be able to insert 
the linear staple in a correct manner.
70, 71
 This may decrease the risk of SBO compared to a 
hand-sewn anastomosis. 
Nonetheless, the biggest RCT (N=328) comparing these two techniques published to date, the 
HASTA-trial
72
 failed to demonstrate a reduction in SBO following a stapled anastomosis. On 
the other hand, two recently published meta-analyses, including the HASTA-trial, confirmed 
that a stapled anastomosis reduced the frequency of SBO by nearly 50%,
71, 73
 in accordance 
with other reports.
70, 74, 75
 Additionally, a stapled anastomosis was associated with a shorter 
operation time and LOS but the frequency of AL from the new anastomosis was not 
influenced.
71-74
  
 
Figure 6. Hand-sewn anastomosis                   Figure 7. Stapled anastomosis 
 
Figure 6 and 7 published with the permission of Wolters Kluwer Health, Inc.  
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Mortality and morbidity after low anterior resection and diverting stoma 
In recent publications, postoperative 30-day mortality after LAR has been reported to be around 
two percent (0-8%).
2, 35, 76
 In Sweden, postoperative mortality has decreased slightly over the 
past 20 years.
2
 
Differences in defining surgical procedures and outcome measures make comparisons of 
morbidity between different studies and centres more difficult. In a meta-analysis regarding AL 
after LAR, the 22 studies included used 12 different definitions of AL.
76
 Moreover, neoadjuvant 
treatment, demographic data, perioperative care, follow-up and registration of postoperative 
morbidity differ between centres. It has been shown that surgeons in training markedly under-
report complications compared with trained study nurses, highlighting the issue of information 
bias.
77
  
A summary of mortality and morbidity after LAR and diverting stoma is shown in Figure 8. 
 
Short-term morbidity after low anterior resection 
Short-term morbidity after LAR (within 30 days after surgery or the initial hospital stay) has 
been reported to be between 20-50%.
2, 78-83
 
Risk-factors described for postoperative morbidity other than AL are male gender, age >70 
years, co-morbidity, perioperative blood transfusion, growth of circumferential tumour, a 
history of deep venous thrombosis and previous abdominal surgery.
2, 80, 81, 83
 
Non-surgical morbidity affects approximately 15-20% of all patients,
78-83
 where infectious 
complications (e.g. pneumonia and urinary tract infections) and cardiac complications are most 
common.
79-81
 
Surgical morbidity varies between 15-25%.
2, 79, 80, 83
 AL, (see section “Anastomotic leakage” 
below) is the most common, most feared and therefore the most discussed complication 
following LAR. However, ileus (1-12%), urinary retention (3-9%), wound infection (1-7%), 
bleeding (1-2%) and wound dehiscence (1%) may also occur.
79, 80, 82-84
 Approximately one in 
ten patients requires emergency reoperation
2, 79
 and the frequency of unexpected readmissions 
in the early postoperative period is around 15%.
2, 78, 79
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Figure 8. Mortality and morbidity after low anterior resection and diverting loop ileostomy. 
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Functional outcome after low anterior resection 
Bowel dysfunction, due to resection of the rectum, damage of the autonomic nerves in the 
pelvis and the sphincter muscles, is common after LAR and has been described in up to 60% of 
all patients.
29, 85
 
The combination of urgency, faecal and/or flatus incontinence and frequent bowel movements 
occurring after LAR is referred to as the Low Anterior Resection Syndrome, LARS.
86
 The 
LARS score, described by Emmertsen et al in 2012, is a commonly used scale to assess LARS 
after LAR.
86
 The questionnaire includes items regarding incontinence for flatus and liquid 
stools, urgency, frequency and clustering (the need of defecate within one hour from the last 
bowel opening) and has been internationally validated.
87
 LARS has been shown to have a 
negative impact on quality of life.
88
 Even though LARS is most common the first year after 
surgery,
31
 approximately 40% still suffer from significant LARS more than two years after 
LAR.
85
 
Construction of a neoreservoir when creating the colorectal anastomosis, regardless of type, has 
been shown to reduce the risk and severity of LARS.
29
 Risk factors, on the other hand, are TME 
surgery, neoadjuvant RT, AL and female gender.
85
  
Urinary dysfunction is mainly caused by nerve damage during surgery, even though pelvic 
inflammation and fibrosis following AL, sutures and RT can be contributing factors.
89
 With 
regard to sexual dysfunction, RT seems to have an additional role. Moreover, the presence of a 
stoma have also been associated with a worse sexual outcome for both genders.
89
 Long-term 
follow-up has reported urinary incontinence in 38%, sexual dysfunction in 60% of female 
patients (dyspareunia and vaginal dryness) and in 75% of men (erectile dysfunction and 
problems with ejaculation).
89
 However, a majority of patients undergoing surgery for rectal 
cancer are older; urogenital function decreases with age, but data suggest that 79% of men and 
52% of women are sexually active at time of rectal cancer diagnosis.
89
 
 
Complications to construction and closure of a diverting stoma  
After construction of a diverting loop ileostomy nearly 50% (3-100%) of the patients have been 
described to suffer from at least one stoma-related complication.
64, 69, 90
 The two most common 
complications are skin irritation (2-41%) and high stoma-flow (18-29%).
69, 90, 91
 The latter can 
lead to severe electrolyte imbalance and renal failure with the need for readmission, reported in 
some studies to be as high as 15%.
64, 69, 90
 Strictures, stoma prolapses and retractions, fistulas, 
parastomal hernias, small bowel obstruction and stenosis can also occur and, in some cases, 
necessitate reoperation.
64, 69
 
Risk-factors that have been suggested to predispose for complications after stoma construction 
are obesity, IBD, increasing patient age, absence of preoperative marking of stoma site and 
evaluation of ET.
64
 
After stoma closure, overall morbidity ranges from two to 40%
64, 68, 69, 90, 91
 and postoperative 
mortality is around 0.5%.
64, 68
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SBO (6-23%), and wound infection (0-18%), are the most common complications.
64, 68, 73, 90
 If 
postoperative SBO does occur, approximately one in three patients require reoperation.
70, 90
 The 
incidence of wound infection has been reported to be significantly lower, 1-5%, if the wound is 
left open or partially open.
64, 68
 
The frequency of AL after stoma closure varies between 0-8% and most instances of AL require 
relaparotomy. Other complications such as fistulas (0-7%) and incisional hernias (1-12%) have 
also been described.
64
 LOS after stoma closure is around two to five days.
64
 
 
Permanent stoma 
A temporary diverting stoma created at LAR ends up as a permanent stoma in 15-25% of 
cases
92-94
 where AL is the biggest risk factor for a permanent stoma.
92-94
 A 6-year follow-up 
study stated that 56% of the patients with AL had a permanent stoma compared to 10% in those 
without a leakage.
94
  
Other risk-factors include increasing age (>65-75 years), secondary constructed stomas, 
postoperative infectious complications, local recurrence, stage IV tumours and co-morbidity.
92-
94
  
The permanent stoma could be either a diverting loop ileo/colostomy or an end colostomy.
93, 94
 
It has been suggested that an end colostomy is preferable as a permanent stoma, due to the 
advantages in stoma handling and a reduced risk of high stoma flow.
94
 
 
Quality of life  
Studies assessing quality of life (QoL) after rectal cancer surgery report differing results due to 
differences in questionnaires used, in type of patients included and outcome measures, making 
interpretation of these results difficult.
88, 95, 96
 
It is suggested that LARS decreases QoL in patients undergoing LAR.
88
 Patients’ body image 
and sexual function are worse compared to before surgery and women have poorer self-reported 
social well-being compared to men.
95
 Despite this, global QoL is generally improved after 
surgery, probably due to patients’ satisfaction that they could possibly be cured from their 
malignancy.
95
 
Besides dealing with the underlying disease and the potential risk of cancer recurrence, stoma 
patients have to face several other challenges such as discomfort, embarrassment and altered 
body image. Simple tasks such as dressing, social activities and swimming may become 
significant obstacles affecting daily life. Even though patients having undergone LAR have a 
better self-reported social function and body image compared to those having undergone APE,
96
 
these improvements might be counterbalanced by the high risk for bowel dysfunction after 
LAR.
29
 A Cochrane review, comparing APE with AR, revealed no difference in global QoL.
97
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Regarding temporary diversion, such as a diverting loop ileostomy, the decreased social 
function and body image correlated with the stoma is not always reversed after stoma closure.
98
  
 
Anastomotic leakage in low anterior resection 
Despite advances in surgical technology and attempts to define risk-factors for AL there has 
been no dramatic change in the incidence of leakage over the last decade.
2, 84, 99
 AL, the most 
feared surgical complication after LAR, seems difficult to predict in the individual patient and it 
has been shown that the surgeon’s prediction of the development of AL has extremely low 
sensitivity and specificity.
100
 
The frequency of AL varies between 3-28%,
76, 84
 likely in part due to differences in the 
definition of AL but also due to actual differences in surgical performance. In an attempt to 
clarify the definition of AL, the International Study Group of Rectal Cancer has suggested a 
definition and grading in rectal cancer surgery (Table 1).
101
 It is noteworthy that this 
classification also includes abscesses close to the anastomosis without radiological verification 
of AL.  
 
Table 1. Definition and grading of AL by the International Study Group of Rectal Cancer 
  
AL causes approximately one third of the early postoperative mortalities, (0.7%; 0-5%) after 
LAR.
76, 102
 
Apart from immediate clinical consequences, such as intra abdominal abscess, peritonitis, sepsis 
and fistulas, with the risk of surgical and radiological re-intervention, AL also increases LOS as 
well as the risk for other complications. In a large cohort study, including more than 70 000 
patients, Kang et al. showed a higher risk of postoperative ileus, wound infection, renal failure, 
urinary tract infections, pneumonia and deep venous thrombosis if AL was present.
102
 
Regarding long-term outcome, AL increases the risk for a permanent stoma
94
 and a worse 
functional outcome.
103
 
Definition 
Defect of the intestinal wall integrity at the colorectal or colo-anal anastomotic site 
(including suture and staple lines of neorectal reservoirs) leading to a communication 
between the intra- and extraluminal compartments. A pelvic abscess close to the 
anastomosis is also considered as anastomotic leakage. 
 
Grade A 
 
Anastomotic leakage requiring no active therapeutic intervention 
 
Grade B 
 
Anastomotic leakage requiring active therapeutic intervention but manageable without re-
laparotomy 
 
Grade C 
 
Anastomotic leakage requiring re-laparotomy 
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It has been suggested that viable cancer cells that remain in the bowel lumen, close to the 
anastomosis, may become extra-luminal following AL, which may lead to local recurrence.
104
 
Moreover, immunosuppression caused by the inflammatory response and delayed adjuvant 
chemotherapy due to AL, could increase the risk for systemic recurrence and cancer-specific 
death.
104
 However, the influence of AL on the risk for disease recurrence and cancer specific 
survival is debated in the literature and a consensus has not yet been reached.
105, 106
 Changes in 
the use of neoadjuvant treatment and implementation of TME surgery over time causes 
difficulties interpreting studies concerning the influence of AL on oncological outcomes. 
 
Risk-factors for anastomotic leakage 
Patient, tumour and therapy-related parameters as well as a disturbed microcirculation have 
found to be risk factors for AL. A recently published meta-analysis, including over 90 000 
patients operated on for CRC, stated that preoperative RT, low rectal anastomosis (≤5 cm from 
the anal verge) and male gender increased the risk for AL in rectal cancer.
107
 In concordance, in 
the 2014 annual report of the Swedish rectal cancer registry, men and irradiated patients had a 
higher risk for AL.
2
 
Preoperative RT initiates local inflammation, fibrosis and micro vascular changes with the risk 
of impaired wound healing. A low anastomosis is sometimes technically demanding to perform, 
and even more so in men where the pelvis is more narrow, leading to local tissue trauma and 
increased tension in the anastomosis as a consequence. In addition, possible poor blood supply 
in the middle and lower rectum could explain the increased risk for AL.
108
 However, even 
though human and animal models have confirmed decreased blood flow in the anastomosis 
after vascular ligation,
104, 109
 it still remains unclear what percentage of normal blood flow that 
is required for intestinal tissue healing.
110
  
Other possible risk-factors for the development of AL are preoperative weight loss and 
malnutrition,
102
 smoking, high consumption of alcohol,
111
 obesity,
112
 intra-operative adverse 
events, prolonged operation time,
113
 absence of pelvic drainage
114
 and the use of non steroidal 
anti-inflammatory drugs after surgery.
115
 
High versus low-tie of the IMA has also been discussed. A high-tie could reduce blood supply 
to the anastomosis by dividing the IMA close to the aorta, including both the superior rectal 
artery and the left colic artery. On the other hand a low-tie has the risk of tension in the 
anastomosis due to a shorter length of the proximal colonic segment. Thus, no difference in AL 
has been found between these two methods.
116
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Diverting stoma and anastomotic leakage 
Several studies have demonstrated a reduction in the frequency of clinically apparent AL if a 
diverting stoma - most often a loop ileostomy - is constructed at LAR.
35-40
 Even though other 
cohort studies have failed to establish this correlation, their biggest limitation is the possible 
selection bias of high-risk patients in the stoma group.
117-122
 
In a Swedish multicentre RCT published in 2007, comparing patients with or without a 
diverting stoma at LAR, the risk for AL was decreased from 28 to 10% in those diverted.
35
 
Hereafter, diverting loop ileostomies created at LAR have increased in Sweden from 
approximately 40% in 2002 to nearly 80% in 2014 (Figure 9 and 10).
2
 Since PME is included 
in these numbers, it is to be assumed that nearly all patients operated on for LAR, with a 
complete TME, are diverted currently.  
The marginal decrease in AL in the Swedish Rectal Cancer Registry during the same period 
(2002-2014) is difficult to interpret. The increasing use of diverting loop ileostomies could be 
one explanation, but as previously mentioned, both PME and LAR are included in these 
numbers and the frequency of AL is not reduced in men and in patients with preoperative RT.
2
 
A report from Snijders et al, from the Dutch Colorectal Surgical Audit (DCSA), did not reveal a 
lower frequency of AL in LAR despite an increased use of diverting stomas.
99
 
In tandem with the increased risk for anastomotic leakage, the need of acute abdominal 
reoperation due to AL is augmented in those without a diverting stoma.
35, 37-39
 A Cochrane 
report from 2010 showed a 77% risk reduction (RR 0.23; 95% CI 0.12-0.42) for acute 
reoperation if a diverting stoma was present.
36
  
 
Figure 9. Use of diverting loop ileostomy at 
anterior resection in Sweden among men.
2
 
 
 
Figure 10. Use of diverting loop ileostomy 
at anterior resection in Sweden among 
women.
2
 
 
 
Figure 9 and 10 published with the permission from the Swedish rectal cancer registry. 
 
Surprisingly, none of the RCT’s or meta-analyses published35-39 have found increased mortality, 
longer LOS or higher readmission rate among patients without a stoma compared to those who 
have been diverted. On the contrary, except for clinical AL and frequency of reoperation, other 
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postoperative morbidity is comparable
79, 123
 and LOS is significantly reduced in those without a 
diverting stoma in some reports.
35, 117, 120
 
Considering long-term morbidity, neither functional nor oncological outcomes have found to be 
influenced by a diverting stoma at LAR.
106, 124
 
 
Late anastomotic leakage  
Late AL, diagnosed after discharge or >30 days after primary surgery, is well known but less 
well described. In the few studies examining this issue, late AL seems to appear in 
approximately six to eight percent of all patients operated on for LAR irrespective of the use of 
a primary diverting stoma or not.
125-127
 Time to diagnosis of late AL ranges between 22-99 days 
after surgery
125-127
 and suggested risk-factors are female gender, low anastomosis and 
neoadjuvant chemo radiation.
127
 
Patients with late AL have been described to have an initial uneventful postoperative course, 
similar to those without a leakage
128
 and a lower rate of relaparotomy
126
 compared with those 
suffering from early AL. Moreover, it has been suggested that late AL treated with a diverting 
stoma has a lower proportion of successful stoma reversal compared with those who suffer an 
early AL.
127
 
 
Experimental treatment for anastomotic leakage 
Several attempts have been made to find alternative treatments to diverting stomas as 
prevention of AL after LAR and to avoid or successfully manage an anastomotic dehiscence. 
The drawbacks with all of these studies are small case-series, selection bias and lack of 
reporting of long-term outcomes. In this section some of the actual treatment options are 
described. 
 
Percutaneous ileostomy 
A jejunal probe introduced in the distal ileum, a percutaneous ileostomy, has been suggested to 
be comparable with a diverting loop ileostomy with regard to the risk of AL in LAR, without 
any increase in other morbidity.
129
 In addition to the advantages of less discomfort for the 
patients and the absence of a stoma, early removal without another surgical procedure may be 
performed. Currently, there is an on-going Italian multicentre RCT, the ALPPI trial, comparing 
these two strategies for diversion in LAR for rectal cancer.
130
  
 
Ghost stoma 
As an alternative to a diverting stoma, some surgeons advocate the use of a ghost stoma. A tube, 
drain or vessel loop is placed around the distal ileum and exteriorised to the abdominal wall. If 
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AL occurs, a loop ileostomy can easily be performed at the site of the tube without the need of a 
relaparotomy.
131
  
 
Intraoperative micro perfusion 
Adequate blood supply to the anastomosis is required for anastomotic healing. Traditionally, 
this is measured by visual lack of decolouration of the dissected colon, palpable pulses in the 
supplying arteries and active bleeding from the resection lines when dividing the intestine. 
However, this macroscopic evaluation may not always correlate with the presence of adequate 
microcirculation in the area. Fluorescence angiography with near-infrared light (NIR) 
technology can be achieved through intraoperative intravenous administration of a fluorescent 
agent. This may give a more objective assessment of the microcirculation along the planned 
resection lines and help guide the decision whether to divide the bowel at the intended site and 
if a diverting stoma is necessary or not.
132, 133
 
 
Perioperative supplemental oxygen 
To improve local oxygenation and perfusion in the anastomosis perioperative supplemental 
oxygen by increased fraction of inspired oxygen (Fi02) has been investigated. Although 
convincing evidence is lacking, improved outcome concerning wound infection and lower rate 
of AL have been observed.
134
 
 
Endo-sponge and early closure 
Vacuum-assisted treatment for different wounds are used to accomplish wound healing. An 
endo-sponge, inserted trans-anally in the cavity that arises after a leakage, and connected to a 
low-vacuum suction bottle has been suggested as a treatment option for AL.
135, 136
 Treatment 
with endo-sponge in the sinus cavity after AL has been successful if the sponge is placed early 
in the postoperative course.
135
 Moreover, initial treatment with endo-sponge followed by 
closure of the anastomotic dehiscence has resulted in healing in some patients.
136
 However, 
except for small series and selected cases, long-term results are lacking.  
 
Transanal tube 
A transanal tube, inserted after the formation of the anastomosis, and kept in place for 
approximately 5 days postoperatively, has been shown to significantly reduce clinical AL even 
in patients without a diverting stoma.
137
 The rationale behind this treatment option is decreased 
intraluminal pressure and improved evacuation of liquid stool proximal to the anastomosis. 
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Fibrin glue 
Some studies have shown that application of fibrin glue over stapled anastomotic lines reduced 
the rate of clinical AL.
138
 Currently, there is an on-going multicentre RCT evaluating this topic 
where preliminary results suggest a lower frequency of leakage in the experimental arm 
(ClinicalTrials.gov number, NCT02046278). 
 
Probiotics and Intestinal microflora 
The role of the intestinal microflora in anastomotic healing and development of AL is largely 
unexplored. Intestinal flora interacts with intestinal tissue and with intestinal healing.
104
 A 
recently published RCT showed a reduction in overall morbidity (49% vs. 29%) and AL, 
specifically (9% vs. 1%), after colorectal cancer surgery if a combination of probiotics were 
given the day before surgery until 15 days after surgery.
139
  
RT has been shown to reduce the amount of bacteria per gram of stool
140
 and to affect 
potentially pathogenic microbes, leading to an enhancement of their virulence causing bacterial 
induced AL. Olivas et al. developed a model, where rats underwent distal colonic resection with 
a colorectal anastomosis.
141
 Some of the rats were preoperatively radiated with 5x5 Gy and 
underwent surgery a week later on and some were inoculated with P. aeruginosa at the end of 
surgery. Rats with both preoperative RT and P. aeruginosa had a higher risk of AL compared to 
those who only were radiated and those who had P. aeruginosa, alone. Moreover, in animal 
models of colonic anastomosis and vessel ligation causing intestinal ischaemia, animals that 
received antibiotics had a decreased risk of AL.
104
 Taken together, the role of intestinal 
microbes in either protecting against or inducing/aggravating AL remains unclear. 
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ENHANCED RECOVERY AFTER SURGERY 
 
Surgical stress, insulin resistance and hyperglycaemia 
Any physical injury, including surgery, induces a metabolic and inflammatory response, 
which disrupts normal homeostasis (Figure 11). 
Cuthbertson first described the metabolic response to injury in 1942 and introduced the 
concept of ebb and flow phase after injury.
142
 The ebb phase begins with a general fuel 
mobilisation, lasting for approximately 24 hours.
142
 Thereafter the flow phase takes place 
with an initial catabolic state. The energy expenditure is elevated and a breakdown of body 
tissues occur. Finally, an anabolic state follows which eventually leads to recovery. 
The stress response is characterised by an elevation of the stress hormones cortisol, 
catecholamines (noradrenaline and adrenaline), glucagon and growth hormone (also known 
as the counter-regulatory hormones) induced by the activation of the hypothalamic-pituitary-
adrenal axis. Moreover, elevation of cytokines generates an inflammatory response.
142
  
 
Figure 11. Metabolic and inflammatory response to surgery 
 
The counter-regulatory hormones stimulate the breakdown of protein, glycogen and fat and 
induce formation of glucose from non-carbohydrate sources (gluconeogenesis) in order to 
ensure supply of energy to vital organs.
142
 In addition, a high level of these hormones leads to 
an insulin resistance, i.e. when a normal concentration of insulin produces a subnormal 
biological response even in non-diabetic patients.
142-144
  
Normally, insulin is released after intake of carbohydrates, protein and fat and acts as an 
anabolic hormone to ensure energy storage and to maintain normal glucose levels.
143
 Even 
though the role of insulin is most studied with regard to glucose metabolism, where it 
stimulates the glucose uptake in insulin-sensitive tissues and suppresses gluconeogenesis in 
the liver, it also plays a role in the storage of fat and protein.
143, 145
 Therefore, in insulin 
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resistance, the inhibitory effects of insulin on gluconeogenesis, glycogenolysis, lipolysis and 
proteolysis is reduced, resulting in hyperglycaemia. Insulin resistance also impairs glucose 
uptake, mainly in skeletal muscle and to some extent also in adipose tissue.
143
 Thus, insulin 
resistance is a key response in the catabolism occurring after surgery. 
Blood loss, type and magnitude of surgery as well as operation time have been found to 
correlate with changes in insulin sensitivity after surgery.
143, 144
 Moreover, a significant 
association between the degree of postoperative insulin resistance, LOS and the development 
of postoperative complications has been shown.
143
 
Hyperglycaemia, caused by the catabolic response and insulin resistance is associated with a 
worse clinical outcome.
144, 146
 Van der Berge et al. conducted an RCT on 1548 surgical 
intensive care unit (ICU) patients, randomised to either receiving intensive insulin therapy 
(blood glucose between 4.4-6.1 mmol per liter) or to conventional treatment (blood glucose 
<10-11.1 mmol per liter).
146
 Mortality was significantly lower in the experimental arm (4.6%) 
compared with the control arm (8%). Furthermore, blood stream infections were reduced by 
46%, acute renal failure by 41%, number of blood transfusions by 50% and critical-illness 
polyneuropathy by 44% in the experimental arm.  
However, intensive insulin treatment can cause hypoglycaemia and may be difficult to 
control outside the ICU. Thus, there is an on-going debate as to what should be the desired 
level of blood glucose control, both in the ICU and on the general ward, in order to balance 
the risk of hyperglycaemia and its attendant risks of morbidity with that of the development 
of hypoglycaemia.  
The pathogenesis behind hyperglycaemia and the observed increased postoperative mortality 
and morbidity is not fully understood. It has been suggested that hyperglycaemia enhances 
the inflammatory response by increasing the expression of proinflammatory cytokines
147
 and 
that it has a negative effect on the immune system by decreasing the function of 
neutrophils.
148
 
 
The ERAS study group, ERAS protocol and ERAS database 
Although surgery by itself induces a stress response, several other peroperative factors 
contribute to the metabolic alterations leading to insulin resistance and hyperglycaemia. The 
concept behind Enhanced Recovery After Surgery, ERAS, is to prevent surgical stress by 
interaction on all of these factors using a standardised evidence-based protocol for 
perioperative care.
149
 ERAS has been shown to attenuate the metabolic response to surgery
150
 
and thereby improving recovery, shortening hospital stay and decreasing postoperative 
morbidity. 
The pioneer behind fast track surgery (the concept that is now known as ERAS) is the Danish 
surgeon Henrik Kehlet. Professor Kehlet demonstrated that a multimodal approach to reduce 
surgical stress (focusing mainly on controlling postoperative pain with as little opiate use as 
possible, to encourage early mobilisation and early oral feeding) shortened LOS after colonic 
surgery.
151
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Influenced by Kehlet et al, the ERAS study group was established in the year of 2000,
152
 
including six European centres, representing five different countries; Ersta Hospital, Sweden, 
Tromsö University Hospital, Norway, Royal Infirmary and St Mark’s Hospital, United 
Kingdom, Maastricht University Hospital, Netherlands and Charité University Hospital, 
Germany. The ERAS Society, established in 2011, involves a large number of institutions 
from all continents. 
All of the participating centres use the same fast recovery protocol, the ERAS protocol, 
carried out by a multidisciplinary team of surgeons, anaesthetists, nurses and 
physiotherapists.
149
 Over 20 evidenced-based perioperative interventions with the aim to 
reduce surgical stress are included.
152
  
To compare outcomes and to measure the effect of the ERAS protocol and the effect of 
different ERAS items on specific outcomes, an international web-based ERAS database has 
been developed. Approximately 140 variables are prospectively collected in the ERAS 
database, from admission to hospital until 30 days after surgery.
152
 Research nurses at each 
centre collect the data, since clinicians have been shown to underreport postoperative 
morbidity.
77
 
The variables, except of the key-components in the ERAS protocol, consist of demographic 
data, perioperative findings and recovery items. Since 2011, postoperative morbidity is 
classified according to Clavien-Dindo
153
 (Table 2, shown in section “Patients & Methods”).  
 
The effect of ERAS in colorectal surgery 
The principles of ERAS, compared with traditional perioperative care in colorectal surgery, 
have been shown to half postoperative overall morbidity, reduce LOS with two to three days 
and to improve postoperative recovery without any increase in readmissions.
78, 154-157
 The 
reduction in postoperative morbidity has been found to be mainly due to a reduction in non-
surgical complications.
78, 154
  
Furthermore, better adherence to the ERAS protocol (compliance over 70%) improves 
postoperative outcome, with reduction in overall morbidity, readmissions and LOS, 
compared with compliance less than 50%.
78, 158
  
The impact of ERAS in rectal surgery, specifically, as opposed to colorectal surgery in 
general has not been thoroughly evaluated. As previously mentioned, grade and severity of 
postoperative insulin resistance is correlated to length and magnitude of the surgical 
procedure and degree of perioperative blood loss.
143
 Although laparoscopy for rectal cancer 
has been suggested to be oncologically safe,
51, 52
 the majority of cancer operations are still 
being performed as open procedures
2
 where tissue damage and blood loss is larger. Thus, 
patients operated on for rectal cancer are likely to suffer from a more severe insulin resistance 
compared to patients with colonic cancer operated on laparoscopically, but can safely be 
treated according to an ERAS program.
149, 159-161
 However, there are some differences in the 
ERAS protocol for rectal/pelvic surgery compared to colonic surgery, especially regarding 
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use of mechanical bowel preparation (MBP), stoma training and early mobilisation (in case of 
reconstruction of the pelvic floor).
149
  
Despite the enhancements, the ERAS concept has been difficult to implement in clinical 
practice. Some of the interventions, such as avoiding drains and MBP in colonic surgery, 
early removal of nasogastric tubes, early mobilisation and oral feeding have to some extent 
been implemented in traditional care. The whole ERAS concept, however, is considered 
complex and resource-demanding. Moreover, the effect of each specific element on 
postoperative outcome remains unclear and studies published so far differ in adherence to the 
protocol and items used. 
 
ERAS interventions 
The aim of each key-component in the ERAS protocol is to reduce surgical stress. In this 
section the ERAS items used in the thesis are described from a rectal surgery perspective 
(Figure 12). 
 
Figure 12. ERAS-interventions used in the thesis 
 
 
Preoperative counselling 
Preoperative information regarding the surgical and anaesthetic procedure and postoperative 
care can reduce fear and anxiety and thereby improve postoperative recovery.
162
 Encouraging 
patients to fulfil different tasks after surgery and involving them in their own treatment may 
facilitate compliance to the ERAS protocol concerning perioperative feeding, early 
postoperatively mobilisation and pain control.  
                      Introduction & Background 
 
43 
 
For patients planned for a temporary or permanent stoma, preoperative training with stoma 
devices and information from the ET have been shown to reduce delayed discharge from 
hospital due to the need for stoma training.
163
 
 
Premedication 
In general, preoperative medication with long-acting sedatives should be avoided as they may 
impair psychomotor function which can make immediate postoperative participation in the 
ERAS protocol difficult.
164
 Although preoperative counselling may reduce fear, many 
patients waiting to undergo rectal cancer surgery still suffer from anxiety. Short-acting 
benzodiazepines can facilitate insertion of epidural and arterial catheters. However, this may 
not be recommended among the elderly, >60 years of age, due to an increased risk of 
postoperative cognitive dysfunction.
165
 
 
No prolonged fasting and Preoperative carbohydrate supplementation 
Traditionally, overnight fasting prior to surgery has been standard practice in order to reduce 
the risk of aspiration pneumonia on induction of general anaesthesia. However, more recent 
data has shown equal rates of aspiration and volumes of gastric content in traditionally fasted 
patients and those allowed intake of clear fluids until two hours before surgery.
166, 167
  
During the night, when sleeping, a state of normal fasting occurs. Before breakfast, when 
there is a lack of circulating substrates and insulin levels are low, glycogenolysis and 
gluconeogenesis are induced in order to maintain normal blood glucose. However, when the 
fasting ends, i.e. breakfast, substrates are freely available, insulin levels increase rapidly and 
the body changes from a catabolic to an anabolic state.
166
  
If surgery is performed after an overnight fast, surgical stress, with its hyper metabolic state 
and insulin resistance, becomes more pronounced. However, postoperative insulin resistance 
may be reduced by about 50% if patients are given oral carbohydrate treatment up until two 
hours before surgery (400 ml, 50 g carbohydrates)
166, 168, 169
 and this may also improve 
control of postoperative blood glucose levels.
170
 In addition, the treatment also results in 
reduced losses of nitrogen and proteins,
171
 which results in improved maintenance of lean 
body mass
172
 and muscle strength.
173
 Furthermore, sense of hunger, thirst and anxiety before 
surgery are decreased.
166
 Moreover, preoperative carbohydrate treatment has been shown to 
be an independent predictor of improved postoperative outcome.
78, 158, 168, 169, 174
 
 
Bowel preparation 
Mechanical bowel preparation (MBP) has been standard of care prior to colorectal surgery 
since the majority of postoperative abdominal infections are caused by colonic flora.
175
 In 
Sweden, it is performed either with polyethylene glycol (PEG, Laxabon®, 4 litres the day 
before surgery) or oral sodium phosphate (NaP, Phosporal®, 45 ml x 2, the day before 
surgery). 
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When MBP is used prior to colonoscopy, adequate bowel cleansing is achieved in 
approximately 70% of patients. 
176
 However, many of patients (50-80%) need help with the 
administration regardless of the type of preparation.
177, 178
 Even though NaP has been 
suggested to have a higher tolerability,
179
 this regime is contraindicated in patients with heart 
and kidney failure due to the higher risk of electrolyte disturbances.
178
 
In colonic surgery, MBP has been abandoned because studies have failed to reveal 
advantages compared with no cleansing.
180-182
 It has been suggested that bowel preparation 
can lead to a more liquid content in the bowel, increasing the risk of spillage during surgery 
and thereby increasing the risk of intra-abdominal infections.
183, 184
 Moreover, MBP causes 
fluid and electrolyte disorders,
185
 a proposed risk-factor for AL,
102
 where dehydration 
increases the need for intravenous infusions.
158
 Furthermore, the procedure is stressful and 
has been shown to prolong postoperative ileus.
177
 
In rectal cancer surgery, MBP is still being performed regularly.
149, 186
 There are no proven 
benefits for mechanical cleansing in high anterior resection or in APE,
180, 181, 184, 187
 but 
regarding LAR with diversion, further studies are required. 
The GRECCAR III trial
188
 compared MBP with no MBP in sphincter-preserving rectal 
cancer surgery where 80% of the patients had a temporary stoma. Significantly higher rates of 
overall and infectious morbidity were found in the non-MBP group as well as a trend towards 
a higher risk of AL and peritonitis. However, in this trial patients without MBP did not 
receive a rectal enema. 
A Cochrane review by Guenaga et al. included a separate subgroup analysis for LAR (n=846) 
and showed a comparable risk for AL in those with and without MBP. They also compared 
MBP with rectal enema (n=195) in LAR, which yielded similar results in both groups.
181
 
Due to inconclusive evidence, MBP is recommended in LAR with a diverting stoma 
according to the current ERAS-guidelines.
149
  
 
Perioperative nutritional supplements 
Fifty percent of patients planned for major gastrointestinal surgery suffer from weight loss 
and malnutrition,
189, 190
 which have been shown to increase the risk of postoperative mortality 
and morbidity.
102, 191-194
 
In rectal cancer, malnutrition can develop secondary to malignancy-related cachexia and 
intestinal obstruction caused by the tumour. Despite this, there is no consensus regarding 
type, regimen and duration of treatment with nutritional supplements as well as to whom it 
might be given.  
There are different ways to measure malnutrition and it still remains unclear which screening 
instrument that best predicts the postoperative risk for nutrition-related complications.
189
 One 
way to measure malnutrition is the Subjective Global Assessment (SGA) questionnaire, 
graded A-C, where grade A represents <5% weight loss, grade B 5-10% weight loss and 
grade C >10% weight loss during the last 6 months.
195
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If possible, enteral nutritional supplements should be given instead of parenteral supplements. 
Enteral nutrition maintains the intestinal mucosa structure and its barrier function. It is also 
less expensive and does not require vascular access with its attendant risks compared to 
parenteral administration.
189, 196
 However, in certain situations, such as severe sepsis, 
malabsorption, intestinal obstruction or when multiple enterocutaneous fistulae are present, 
TPN might be the only way to improve nutritional status.
189
  
So far, the major benefit of perioperative nutritional intervention has been seen in severely 
malnourished
191-194, 197
 patients treated with perioperative TPN. However, administration of 
TPN in well-fed patients has been proven harmful with a higher rate of infectious 
complications.
191, 196, 197
 
Preoperative treatment with ONS has not been proven to affect postoperative outcome
197-199
 
but some studies indicate a lower rate of weight loss and morbidity if given peri-
200
 and 
postoperatively.
201, 202
 
The ERAS protocol recommends ONS as a complement to normal oral intake to reach the 
recommended daily intake (RDI).
149
 In cases of severe malnutrition, i.e. patients in the SGA-
C category, nutritional support for 7-10 days pre- and postoperatively should be given.
203
 
 
Immunonutrition 
The amino acid arginine, naturally ingested, becomes deficient in plasma within hours after 
surgery.
204
 Normally, arginine plays a role in nitric oxide (NO) production and T- lymphocyte 
function. As a consequence of arginine depletion, vasodilatation and microcirculation is 
impaired (due to absence of NO) and T-lymphocyte dysfunction is induced.
204
 Glutamine, 
another amino acid, has been shown to aid preservation of small bowel function and the 
function of T-lymphocytes after major surgery
189
 and omega-3 fatty acid reduces the 
inflammatory response.
205
 
Oral nutritional treatment enriched with immune-modulating substrates such as arginine, 
glutamine and omega-3 fatty acid, called immune-enhancing diets (IE), has gained 
acceptance as a modulator of surgical outcome. Perioperative IE, even when given to well-
fed patients, has been associated with improved postoperative outcome by reduction of 
infectious complications and LOS.
189, 197, 204, 206
  
Still, there is no consensus regarding standard dosage of these immune modulating substrates, 
i.e. which component is the most important, and the timing of administration.
204, 205
 Several 
ONS regimes contain immune modulating substrates in lower dosage and a recently 
published meta-analysis, found no benefit of IE over ONS in the preoperative setting.
205
   
 
Perioperative fluid management 
Several factors may influence fluid balance in rectal cancer surgery, such as preoperative 
dehydration caused by malnutrition and/or MBP, open surgery or excessive blood loss. 
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Additionally, intraoperative hypothermia, use of EDA and anaesthetic drugs can cause 
vasodilatation leading to haemodynamic instability. 
Perioperative fluid overload can cause tissue oedema leading to impaired tissue-oxygenation 
and delayed recovery of gastrointestinal function.
207
 A liberal fluid management, i.e. no 
restriction regarding intravenous infusions, is associated with an increased risk of 
postoperative complications and LOS after major abdominal surgery.
208-210
 However, 
hypovolaemia may impair organ perfusion and oxygen delivery and thereby cause 
gastrointestinal dysfunction.
211
 
Thus, individualised fluid replacement therapy to maintain the patient in a normovolaemic, 
balanced fluid state seems to be preferable.
209,
 
210, 212
 
To optimise cardiac stroke volume, peroperative cardiac output can be measured with an 
oesophageal doppler, and the right amount of infusions and inotropic drugs can be titrated to 
enhance oxygen delivery. This goal-directed therapy has been suggested to improve 
postoperative outcome.
211
 Yet, recently published trials have failed to show any benefit of 
this intervention versus restrictive fluid treatment conducted in an ERAS setting.
213
 
Moreover, a balanced fluid approach, resulting in a maintained postoperative body weight, 
has been found comparable to oesophageal doppler.
212
  
  
Epidural catheter  
Afferent nerves from the site of injury are of major importance for activation of the metabolic 
stress response.
214
 A continuous EDA, inserted before initiation of surgery, blocks the 
afferent nerves and attenuates the increase in counter regulatory hormones and insulin 
resistance.
214
  
Sufficient analgesia, to allow early mobilisation and oral feeding while avoiding opioids, is 
one of the corner stones in the ERAS concept. An EDA, kept in place for two to three days 
after surgery, reduces pulmonary complications, rate of postoperative ileus and allows early 
mobilisation. 
In the era of minimal invasive surgery spinal anaesthesia may be sufficient with regard to 
pain-relief and has been shown to enhance gastrointestinal motility and reduce hospital stay 
compared to EDA.
215
  
 
Intraoperative warming 
Mild hypothermia (a 1-3°C fall in core temperature) is common during surgery.  Operating 
rooms are cold while anaesthetic drugs interfere with normal thermoregulation.
216, 217
 The 
skin is the dominant source of heat loss but evaporation from large skin incisions can also 
contribute to hypothermia.
217
 
Even mild hypothermia increases the stress response and is associated with adverse outcomes 
after surgery.
216
 Higher rates of wound infections, development of coagulopathy, cardiac 
events as well as a prolonged LOS have been reported.
217
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With administration of warm (37°C) intravenous fluids during surgery, use of laparoscopic 
technique when suitable and by covering the skin with forced-air heated warming blankets, 
the core temperature can be maintained and the stress response diminished.
149, 217
 
 
Early mobilisation 
After surgery, bed-rest increases insulin resistance,
218
 muscle loss and impairs pulmonary 
function.
151
 Early mobilisation may decrease the risk for thromboembolic events and 
pulmonary complications.
151
 Thus, mobilisation for more than two hours the day of surgery 
and thereafter more than six hours per day until discharge are warranted according to the 
ERAS-protocol.
149
 However, patients with flap reconstruction of the pelvic floor are 
excluded, as they require a special physiotherapy regime. 
 
Early oral intake 
Oral intake, within the first 24 hours after surgery, may decrease postoperative insulin 
resistance
218
 and nitrogen losses.
170
 Improved surgical outcome without any differences in 
rate of AL has been reported with this regime.
219, 220
  
 
Early removal of drains and catheters 
By early removal and avoidance of unnecessary drains, compliance with early oral intake and 
mobilisation can be improved. 
Nasogastric decompression increases time to first bowel movement, LOS, discomfort for the 
patients and is combined with a higher risk for respiratory infections.
221, 222
 The routine use of 
nasogastric tubes should therefore be avoided. If inserted during surgery, removal should take 
place before reversal of anaesthesia.
149
 
Traditionally, a pelvic drain is placed near the rectal anastomosis to evacuate blood and 
serous collection to prevent AL. A Cochrane review has failed to show any benefit of pelvic 
drainage after elective rectal surgery and therefore, this routine is not recommended.
149, 223
 
If EDA is used in open rectal cancer surgery, a urinary bladder catheter - placed through the 
urethra or suprapubic - is inserted to avoid urinary retention. In patients without risk-factors 
for prolonged urinary retention, early removal (day one after surgery) seems not to increase 
the risk of urinary retention, even if the EDA is left in place.
224
 Moreover, a reduction in 
urinary tract infections and LOS has been reported.
224
 When risk-factors for urinary retention 
are present, a suprapubic catheter is preferable. Compared with transurethral catheterisation, 
the suprapubic route is associated with less urinary tract infections and patient discomfort.
225
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RATIONALE FOR FURTHER RESEARCH 
 
 
During the last decades, two main interventions aiming to prevent or reduce morbidity in 
rectal cancer surgery have been introduced; the use of a diverting loop ileostomy in LAR and 
perioperative fast track programs, such as ERAS. 
Even though a diverting stoma has been reported to decrease clinical anastomotic leakage, no 
dramatic change in leakage rate over time has been noticed parallel with the increased stoma 
use. Moreover, stoma-related complications are added to the existing morbidity after LAR.  
Previous studies on AL and diverting stomas have been designed in a traditional perioperative 
care setting and the main focus has been on short-term morbidity. 
It is still unknown if ERAS (known to improve outcome after colorectal cancer surgery), 
influences the effects of a diverting stoma in LAR and if long-term results are affected by a 
temporary diversion. Furthermore, it is unclear if the type of anastomosis affects the 
incidence of SBO, one of the major complications after stoma closure. 
Despite unclear evidence, MBP is often used in rectal cancer surgery due to the colonic 
diversion. This type of bowel cleansing can cause fluid shifts and electrolyte imbalance, 
suggested risk factors for AL and a worse postoperative outcome. If ONS can be an 
alternative to traditional MBP, the negative side effects with this procedure may be avoided 
and perhaps the postoperative course could be improved further. 
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AIMS OF THE THESIS 
 
 
The overall aim of this thesis was to optimise and evaluate the treatment for patients with a 
diverting loop ileostomy in rectal cancer surgery. 
 
The specific aims were to evaluate: 
 
- Short-term morbidity after low anterior resection in relation to a diverting loop 
ileostomy and ERAS 
 (Paper I) 
 
- Long-term morbidity after low anterior resection in relation to a diverting loop 
ileostomy 
  (Paper II) 
 
- Postoperative complications after closure of a diverting loop ileostomy in relation to 
type of anastomosis.  
 (Paper III) 
 
- If bowel preparation can be safely achieved by nutritional supplements and if this 
routine affects postoperative morbidity, nutritional and physiological status in patients 
operated on for rectal cancer 
 (Paper IV) 
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PATIENTS & METHODS 
 
 
The regional ethics committee approved each of the four studies. A summary of patients and 
methods, paper I-IV, is shown in Table 2. 
 
Table 2. Summary of Patients and Methods, paper I-IV 
 
Paper 
 
 
Design 
 
Number of patients 
 
 
Data collected 
 
Exposure/Outcome 
 
I 
 
 
Prospective cohort 
study 
 
 
287 
 
 
Jan 2002- 
Dec 2011 
 
Diverting loop 
ileostomy or not at 
LAR and ERAS / 
Short-term 
morbidity 
 
II 
 
 
 
 
III 
 
 
Retrospective 
cohort study 
 
 
 
Retrospective 
cohort study 
 
 
287 
 
 
 
 
351 
 
Jan 2002- 
Dec 2011 
 
 
 
Oct 1999- 
Dec 2006 
 
Diverting loop 
ileostomy or not at 
LAR / Long-term 
morbidity 
 
Type of anastomosis 
at closure of 
diverting loop 
ileostomy / 
Postoperative 
complications  
 
IV 
 
 
Randomised 
controlled trial 
 
 
29 
 
June 2008- 
Feb 2013 
 
ONS or PEG before 
rectal cancer surgery 
/ Bowel cleansing, 
nutritional and 
physiological 
outcome and short-
term morbidity 
 
 
PAPER I 
A prospective cohort study was conducted. The cohort consisted of all patients who 
underwent LAR (complete TME) for rectal cancer at Ersta Hospital, between 8
th 
of January 
2002 and 27
th
 of December 2011. All patients were treated according to the ERAS protocol 
and were prospectively registered in the ERAS database. There were no exclusion criteria.  
Between 2002-2006, 15% of the patients included had a diverting loop ileostomy during 
LAR, compared to 91% during 2007-2011 (Figure 13). Except for the increased use of 
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diverting loop ileostomies, there were no other major differences in surgical techniques, 
perioperative care or participating surgeons during the study period. 
Data on patient characteristics, operative and postoperative outcomes were collected from the 
ERAS database. The Clavien-Dindo classification of postoperative morbidity was performed 
retrospectively. 
 
Figure 13. Use of diverting loop ileostomy in LAR, 2002-2011, paper I and II 
 
 
Definitions 
LAR was defined as a complete TME according to the medical records.  
Postoperative morbidity was classified according to the Clavien-Dindo classification,
153
 
(Table 3). The category “Other” included renal failure and uncontrolled hyperglycaemia. 
 
 
 
 
 
 
 
 
 
 
% 
Year       2002           2003          2004          2005          2006        2007         2008         2009          2010         2011           
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Table 3. The Clavien-Dindo classification of postoperative morbidity 
 
 
Clinical AL was defined as symptoms (abdominal pain with elevated CRP, peritonitis, 
faeces/air to vagina or urinary bladder, faeces/pus from abdominal drainage, pelvic abscess) 
in combination with radiological or operative findings confirming the diagnosis. 
Moreover AL was graded A-C, according to the classification proposed by the International 
Study Group for Rectal Cancer,
101
 table 1. Grade A; AL results in no change in patients’ 
 
Infectious   Pneumonia 
Septicaemia 
Other 
 
Cardio/ 
Pulmonary   Acute cardiac infarction 
Congestive heart failure 
Cardiac arrhythmia 
Deep venous thrombosis 
Other 
 
Neurological   Cerebral vascular injury 
Other 
 
Surgical   Wound infection 
Intraabdominal infection 
Wound dehiscence 
Bleeding 
AL 
Stoma problems 
Urinary catheter in situ on discharge from hospital 
Other 
Other 
 
 
Grade 1 Any deviation from the normal postoperative course without the need for pharmacological 
treatment or surgical, endoscopic and radiological interventions. 
Allowed therapeutic regimens are: antiemetics, antipyretics, analgetics, diuretics and 
electrolyte supplementation and physiotherapy. This grade also includes wound infections 
opened at the bedside. 
Grade 2 Complications requiring pharmacological treatment with drugs other than those allowed for 
grade I. Blood transfusions and total parenteral nutrition are also included. 
 
Grade 3 Complications requiring surgical, endoscopic or radiological intervention. 
 
Grade 3a Intervention not under general anaesthesia 
Grade 3b Intervention under general anaesthesia 
 
Grade 4 Life-threatening complication requiring ICU-management. 
 
Grade 4a Single organ dysfunction 
Grade 4b Multi-organ dysfunction 
 
Grade 5  Death of the patient. 
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management, grade B; AL requires active therapeutic intervention but no relaparotomy and 
grade C; AL requires relaparotomy.  
Acute reoperations included conditions requiring general anaesthesia; relaparotomy, 
endoscopic evaluation of neorectum and pelvic drainage. 
 
The Recovery items used in the ERAS database were assessed on the first postoperative day 
when the patient: 
- Ate full meals of solid food 
- Had no intravenous infusion, drip down 
- Was out of bed >6 hours 
- EDA catheter was removed, EDA stop 
- Urinary catheter was removed, (in paper I named KAD drawn) 
- Had their first flatus 
- Had their first stool 
- Fulfilled all of the included recovery items 
 
To measure ERAS compliance, several key components in the ERAS protocol were analysed. 
The items were divided into pre-and postoperative items and compliance rate was calculated 
in percent. 
Preoperative ERAS items (compliance if “yes”): 
- Preadmission counselling 
- Preoperative bowel preparation 
- Carbohydrate drink 
- No premedication 
- EDA 
- Intraoperative warming (using a Bairhugger® blanket) 
- Oral fluids on the day of surgery 
- Less than 3500 ml of intravenous fluids on the day of surgery  
Postoperative ERAS items measured at postoperative day 1 (compliance if “yes”): 
- No intravenous infusion 
- Out of bed >6 hours 
- Intake of  >600 ml of ONS 
- Intake of solid food 
 
Exposure was a diverting loop ileostomy or not at LAR. Primary outcome was postoperative 
morbidity, including AL, within 30 days after surgery and secondary outcomes were 
postoperative recovery and LOS. 
 
           Patients & Methods 
55 
 
PAPER II 
A retrospective cohort study was conducted. The cohort was the same as described in Paper I, 
i.e. all patients operated on for LAR, with or without a diverting loop ileostomy at Ersta 
Hospital, Sweden. The study period was between 8
th 
of January 2002 and 27
th
 of December 
2011 and all patients were prospectively registered in the ERAS database.  
All patients had repeated follow-up (4-6 weeks, then one, two and three years) after surgery 
with clinical examination, pelvic MRI and CT scan of the thorax and abdomen according to 
an oncological protocol. In addition, before closure of the stoma, a CT scan with rectal 
contrast and a flexible sigmoideoscopy to assess integrity of the anastomosis was performed. 
Data on long-term morbidity and permanent stoma was collected from medical records. 
Follow-up time was until 3 years after LAR. 
 
Definitions 
Long-term morbidity was defined as late AL, late readmissions (>30 days until 3 years after 
LAR, due to late AL, stoma problems and/or ileus), postoperative complications after stoma 
closure, oncological outcome and permanent stoma. 
Late AL was leakage occurring more than 30 days until 3 years after LAR. Symptoms 
(abdominal pain with elevated CRP, air/faeces from bladder or vagina and abdominal 
abscess) in combination with radiology were mandatory. 
A stoma was considered permanent when a decision not to reverse the stoma was 
documented in the medical records. This included stomas created at LAR, stomas created 
later on and any secondary stomas constructed due to AL. 
Repeated surgery was planned surgery for stoma closure and unplanned surgery for AL, 
stoma formation or ileus, 30 days to 3 years after LAR. 
In the variable LOS+, all LOS (from 30 days to 3 years after LAR) due to late readmissions, 
formation of first or secondary stomas and stoma closure were combined. 
 
Exposure was a diverting loop ileostomy, or not, at LAR. Primary outcome was long-term 
morbidity within 3 years after surgery and secondary outcome was LOS+. 
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PAPER III 
A retrospective cohort study was conducted. The cohort consisted of all patients operated on 
for closure of a diverting loop ileostomy at Uppsala University Hospital, Karolinska 
University Hospital, Huddinge and Karlstad Central Hospital, between 1
st
 of October 1999 
and 31
th
 of December 2006. Exclusion criteria were stoma constructed during cytoreductive 
surgery and incomplete available information in the medical record (14 patients). 
Data regarding demography, previous surgery, type of anastomosis, postoperative 
complications within 30 days after surgery and LOS were collected from medical records.  
 
Definitions 
Type of anastomosis for closure of the diverting loop ileostomy was divided into two groups, 
hand-sewn (HS) and stapled (S) anastomosis. The HS-group was also divided into HS with or 
without a small bowel resection. Surgeon preference and local traditions dictated the choice 
of anastomosis.  
Previous abdominal surgery was defined as at least one previous abdominal surgical 
procedure, stoma construction not included. 
The surgeon experience was divided into four categories, A-D. Grade A represent Surgical 
registrar, B; General surgeon, C; Senior registrar (colorectal surgery) and D; Consultant 
surgeon (subspecialist accreditation in colorectal surgery). 
Postoperative complications were divided into SBO, AL and need of acute reoperation. 
SBO was defined as symptoms (nausea, vomiting, abdominal pain and absence of bowel 
movements, either gas or stool) in combination with radiology - plain abdominal x-ray or 
abdominal CT scan followed by water-soluble contrast. 
AL was either confirmed with radiology and/or intraoperative findings. 
 
Exposure was type of anastomosis during the closure procedure and outcome was 
postoperative complication within 30 days after surgery. 
 
PAPER IV 
A single-centre randomised controlled trial was conducted at Ersta Hospital, between 11
th
 of 
June 2008 and 5
th
 of February 2013 (ClinicalTrials.gov number, NCT00687570). 
All patients planned for rectal cancer surgery, without severe dementia, distant metastases at 
diagnosis or symptoms of acute intestinal obstruction were asked to participate. Informed 
consent was mandatory.  
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Randomisation took place 4-6 weeks before surgery and was stratified for type of surgical 
procedure (open/laparoscopic) and the absence or presence of tumour-induced stricture. 
Sealed envelopes were used with information on group allocation. Patients were randomised 
to one of the two treatments arms, Oral Nutritional Supplements (ONS)-group or 
Polyethylene Glycol (PEG)-group. 
 
ONS-group 
From randomisation until one week before surgery 50% of the RDI of energy (30 
kcal/kg/day) was provided as ONS (Fresubin®, residue free, 300 kcal/200 ml). The last week 
before surgery, ONS provided the entire RDI of energy ensuring a residue free diet. The 
evening before and the day of surgery two rectal enemas (Klyx®, 240 ml) were given and no 
further MBP was used. 
 
PEG-group 
Patients in this group had no change to their normal diet during the same period. The day 
before surgery MBP was given with 4 L of PEG (Laxabon®). 
Prior to randomisation, 1 day before surgery, 3 days and 4 weeks after surgery, measurements 
of nutritional status (SGA, weight, BMI, upper arm circumference, percent total body and 
subcutaneous fat) and physiological tests (spirometry and handgrip strength) were performed 
and quality of life was assessed (European Organisation for Research and Treatment of 
Cancer (EORTC QLQ-30)
226
 and Abdominal Surgery Impact Scale (ASIS)).
227
 
Physical activity was determined with a pedometer, three weeks before until five days after 
surgery and patients also registered their daily intake of calories from randomisation to the 
day before surgery (one weekday and one day during the weekend). 
Peroperatively, surgeons examined the degree of colonic and rectal cleansing according to a 
standardised protocol (“empty”, “half full”, “full”). 
All patients were treated according to the ERAS protocol and data on patients’ characteristics 
and postoperative outcome were collected from the ERAS database. Postoperative morbidity 
was classified according to Clavien-Dindo (Table 2) and the same recovery items as in Paper 
I were used. 
A flow-chart of the different steps in the study is shown in Figure 14. 
 
Exposure was ONS without MBP or preoperative MBP with PEG before rectal cancer 
surgery. Outcome measures were peroperative degree of bowel cleansing, perioperative 
nutritional and physiological outcome and postoperative morbidity.   
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Figure 14. Flow-chart, paper IV 
 
 
 
 
 
 
STATISTICAL ANALYSES, PAPER I-IV 
All values are presented as mean±SD, median with range and OR with 95% CI, where 
appropriate. For comparison of categorical variables, Pearson’s X2 test or Fisher’s exact test 
was used. A two-tailed t-test or the Mann-Whitney U-test was used for comparison of 
continuous variables. 
Baseline characteristics were analysed to determine the unadjusted association between the 
univariate predictors and the outcome variables clinical AL (Paper I), late AL and permanent 
stoma (Paper II) and postoperative complication (Paper III). A p-value <0.15 was considered 
relevant for the univariate predictor to be included in the multivariate analysis. 
Multiple logistic regression was performed to determine the adjusted association between the 
different predictors and the outcomes. In Paper I and II the variables included in the 
multivariate analysis were age, BMI, gender, ASA score, preoperative radiotherapy and 
chemotherapy, stage of the tumour, type of anastomosis and diverting loop ileostomy at LAR. 
In Paper III, adjusting variables were gender, ASA score, BMI, previous abdominal surgery, 
surgeon experience and the reason for diverting loop ileostomy. 
For calculation of repeated measurements in Paper IV (i.e. physiological and nutritional data) 
one-way ANOVA and paired t-tests were conducted. 
A p-value <0.05 was considered statistically significant. 
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Power calculation 
In Paper IV, the study hypothesis was that 25% of the patients in the ONS group would lose 
two kilograms in four weeks preoperatively, compared to 75% in the PEG-group. With 80% 
power and a one-sided 95% CI, the number of patients needed in each group for detecting a 
difference in preoperative weight loss was 18 patients. The data were analysed according to 
the intention-to-treat principle. 
All statistical analyses were calculated with Stata® version 10.0 (StataCorp, College Station, 
Texas) in Paper I-II and IV.  
In Paper III, all statistical analyses were made using Statistica® software (Stat soft, Tusla, 
USA).  
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RESULTS  
 
 
PAPER I 
Demographic and preoperative data 
During the study period 2002-2011, a total of 287 patients underwent LAR for rectal cancer, 
139 with a diverting loop ileostomy (S+) and 148 patients without a diversion (S-). 
Between 2002-2006, 162 patients underwent LAR, 15% with a diverting loop ileostomy. 
During 2007-2011, 125 patients underwent surgery, 91% with a diverting loop ileostomy. 
The cohort was divided into S+ and S- and into groups depending on the time period (2002-
2006 and 2007-2011) as shown in Figure 16. 
 
Figure 16. Cohort divided in S+/S- and time-periods 
 
 
The groups, S+ and S-, were comparable regarding demographic data, preoperative MBP, 
tumour level and stage of the tumour (Table 4). 
In each group, 113 patients (81% in S+ and 76% in S-, P=0.306) had preoperative RT. 
Nineteen (14%) patients received preoperative chemotherapy in the S+ compared to none in 
the S-, P<0.001. 
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Table 4. Patient characteristics and preoperative data divided in S-/S+ and time-periods 
  
S- 
n=148 
 
S+ 
n=139 
 
 
p-value 
   
2002-2006 
n=162 
 
2007-2011 
n=125 
 
p-value 
 
Age (median) 
 
 
65(29-
86) 
 
62(30-84) 
 
 
0.097
2 
   
64(29-86) 
 
63(30-84) 
 
0.484
2 
 
Gender M/F  
 
 
 
85/63 
(57/43) 
 
87/52 
(63/37) 
 
 
0.373
1 
   
93/69 
(57/43) 
 
79/46 
(63/37) 
 
0.321
1 
 
ASA I/II/III  
 
 
 
40(27) 
99(67) 
9(6) 
 
 
32(23) 
94(68) 
13(9) 
 
0.481
1 
   
44(27) 
106(66) 
12(7) 
 
28(22) 
87(70) 
10(8) 
 
0.653
1 
 
BMI (median) 
 
 
25(19-
42) 
 
25(16-35) 
 
0.554
2 
   
25(19-42) 
 
25(16-35) 
 
0.868
2 
 
Preoperative MBP  
 
 
130(89) 
 
 
117(84) 
 
 
0.227
1 
   
142(89) 
 
103(82) 
 
0.093
1 
 
Preoperative 
RT 
 
 
113(76) 
 
113(81) 
 
 
0.306
1 
   
121(75) 
 
103(84) 
 
0.056
1 
 
Preoperative 
chemotherapy 
 
 
0 
 
19(14) 
 
<0.001
1 
   
2(1) 
 
17(14) 
 
<0.001
1 
 
Tumour level  
(from anal verge) 
 
Group 0=0-5 cm 
Group 1=6-10  
Group 2≥11 cm 
 
 
 
 
 
4(3) 
89(61) 
53(36) 
 
 
 
 
3(2) 
102(73) 
34(25) 
 
 
 
 
0.082
1 
   
 
 
 
4(2) 
100(63) 
56(35) 
 
 
 
 
3(2) 
91(73) 
31(25) 
 
 
 
 
0.173
1 
 
Stage I/II/III/IV 
 
 
50(34) 
47(32) 
44(30) 
6(4) 
 
46(33) 
33(24) 
55(40) 
5(3) 
 
 
0.295
1 
   
59(37) 
43(27) 
53(33) 
6(3) 
 
37(30) 
37(30) 
46(37) 
5(3) 
 
0.666
1 
Percentage in brackets unless indicated otherwise. 
1
 Pearson’s X2 test, 2  t-test 
 
In concordance, when the two time-periods (2002-2006 and 2007-2011) were compared 
regarding demography and preoperative data, preoperative chemotherapy was the only 
significant difference between the groups (Table 4).  
In the following, only S+ and S- are compared. 
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Operative data 
Two hundred eighty three out of 287 operations were performed as open procedures, while 
four patients underwent a laparoscopic resection. End-to-side anastomosis was most common 
and performed in 254 patients (S+ 99%, S- 79%, P<0.001). The level of anastomosis, from 
the anal verge, was in median 4 cm in both groups, P=0.200.  
Operation time was longer in the S+ group compared to S- group (median 222 and 185 
minutes, respectively; P<0.001). 
 
Postoperative data 
Postoperative morbidity occurred in 48% of all patients, 53% in S+ and 43% in S- (P=0.116) 
and did not differ between the groups (Figure 17). 
 
Figure 17. Postoperative morbidity classified according to Clavien-Dindo 
 
Number presented as percentage. 
1
 Pearson’s X2 test, 3 Fisher’s exact test 
 
Pneumonia and urinary tract infection were the most common infectious complications in 
both groups. 
The frequency of surgical complications and acute reoperations are shown in Table 5. There 
was no significant difference in the frequency of clinical AL in the univariate analysis, 19% 
(27 patients) in S+ and 24% (36 patients) in S- (P=0.316) or in the multivariate analysis (OR 
0.64; 95% CI 0.34-1.19). 
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The need for acute relaparotomy, due to AL and other causes, did not differ between the 
groups (S+ 11 patients, S- 22 patients, P=0.065).  
Twenty patients underwent reoperation due to grade B and C AL in the S+ group compared 
with 31 patients in S- (P=0.146). Acute relaparotomy due to AL, grade C, was significantly 
more common in the S- group (21/148 or 14% vs. 3/139 or 2%, P<0.001)  
 
Table 5. Surgical morbidity and acute reoperations 
  
S+ 
n=139 
 
 
S- 
n=148 
 
p-value 
 
Surgical morbidity 
 
 
50(36) 
 
47(32) 
 
0.451
1 
Clinical AL 27(19) 36(24) 0.316
1 
Ileus 3 1  
Hematoma  1  
Intra abdominal abscess  1  
KAD at discharge 4 6  
Wound infection 2 2  
Bleeding 1   
High stoma flow 9   
Wound dehiscence 3   
Ischemia of a part of the 
stomach 
1   
 
Acute relaparotomy 
 
 
11(8) 
 
22(15) 
 
0.065
1 
 
Acute relaparotomy, AL 
(Grade C) 
 
 
3(2) 
 
21(14) 
 
<0.001
1 
 
Acute reoperations, AL 
(Grade B, C) 
 
 
20(14) 
 
31(21) 
 
0.146
1 
Percentage in brackets. 
1 Pearson’s X2 test 
 
Time until patients were mobilised (out of bed >6 hours), had no intravenous infusion and 
fulfilled all discharge criteria were significantly longer among S+ compared to S-, while other 
variables measured in postoperative recovery were comparable (Table 6). 
Total compliance with pre- and postoperative ERAS items was 65% in the entire cohort, 
slightly higher in S+ (69%) compared to S- (61%), P<0.001. Preoperative compliance was 
also higher in S+ (77%) vs. S- (68%), P<0.001, whereas postoperative compliance did not 
differ (S+ 46%, S- 47%, P=0.994). In a multivariate analysis, compliance to ERAS did not 
influence the frequency of clinical AL. 
          Results 
65 
 
There was no difference in readmissions (S+ 17%, S- 14%, P=0.472) within 30 days after 
surgery or in LOS (in median (range), S+ 11(4-53) days and S- 9(3-68), p NS) between the 
groups. 
 
Table 6. Postoperative recovery.  
  
S+ 
n=139 
 
 
S- 
n=148 
 
p-value 
 
Solid food 
 
 
1(0-14) 
 
1(0-11) 
 
0.162
4 
 
Drip down 
 
 
3(0-48) 
 
2(0-42) 
 
0.038
4 
 
Out of bed >6 h 
 
 
3(1-28), mean 6 days 
 
3(1-68), mean 4 days 
 
0.006
4 
 
EDA stop 
 
 
4(1-17) 
 
4(2-27) 
 
0.418
4 
 
Urinary catheter removed 
 
 
5(2-23) 
 
5(2-29) 
 
0.865
4 
 
First flatus 
 
 
2(0-13) 
 
2(0-16) 
 
0.591
4 
 
First stool 
 
 
3(0-13) 
 
3(1-19) 
 
0.125
4 
 
Fulfil all  
 
 
8(2-52) 
 
5(2-68) 
 
<0.001
4 
All values are presented as median (range) in days after surgery. 
4 
Wilcoxon rank sum test 
 
Time-periods 
All calculations were performed between the two time-periods, 2002-2006 and 2007-2011. In 
accordance with the above results, preoperative chemotherapy, operation time, type of 
anastomosis and compliance to the ERAS protocol were the only variables that differed 
significantly between the two periods. 
Moreover, when the 36 patients that differed in surgical approach within each time-period 
(i.e. 25 patients with a diverting loop ileostomy 2002-2006 and 11 patients without a 
diverting loop ileostomy 2007-2011) were excluded, the same results were found. 
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PAPER II 
For demography, preoperative and operative data see Paper I, Table 4. The cohort consisted 
of 287 patients, 139 in S+ and 148 in S-, all operated on with LAR for rectal cancer. 
 
Long-term morbidity 
A total of 17 patients (6%) developed late AL in the entire cohort, with no difference between 
the groups (S+ 6%, S- 5%, P=0.701). In a multivariate analysis, a diverting loop ileostomy at 
LAR did not reduce the risk for late AL (OR 0.84; 95% CI 0.28-2.46). 
The median time to diagnosis of late AL was 83 (range 34-1021) days in S+ compared to 184 
(34-802) days in S- (P=0.531). Of the 17 patients with late AL, 14 were diagnosed within the 
first year after LAR. 
The frequency of late readmission due to AL, stoma problems or ileus was 16% (22 patients) 
in S+ and 15% (22 patients) in S-, P=0.808. AL and ileus were the most common cause for 
late readmission in both groups (Table 7). 
LOS was significantly longer in S+ compared to S-, (mean LOS 7 and 4 days), respectively, 
P<0.001 (15 vs. 10 days if LOS within 30 days after LAR was included, P<0.001). 
 
Table 7. Late readmissions 
  
S+ 
n=139 
 
 
S- 
n=148 
 
p-value 
 
Late readmission 
 
 
22(16) 
 
22(15) 
 
0.808
1 
 
Anastomotic leakage 
 
 
8(36) 
 
17(77) 
 
0.085
1 
 
Ileus 
 
 
9(41) 
 
5(23) 
 
0.224
1 
 
High stoma flow 
 
 
5(23) 
 
0 
 
0.020
1 
1
 Pearson’s X2 test 
 
The overall frequency of postoperative complications after stoma closure was 9% (SBO; 5 
patients, bleeding from anastomosis; 2 patients, wound dehiscence; 1 patient). There was no 
AL from the new anastomosis and no postoperative mortality. 
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Total recurrence (systemic and loco-regional) and cancer specific death within 3 years after 
LAR did not differ between S+ and S-, 22% vs. 24% (P=0.786) and 10% vs. 8% (P=0.709), 
respectively. One patient in S+ had local recurrence compared to 3 patients in S-. AL did not 
increase the risk for total recurrence or cancer-specific death. 
Twenty-three patients (17%) in S+ and 20 patients (14%) in S- had a permanent stoma during 
the 3-year follow up (P=0.742), (Table 5). In S+, in presence of AL, 47% had a permanent 
stoma compared to 39% in S- (NS) and in a multivariate analysis, AL was the only factor 
increasing the risk for a permanent stoma (OR 20.98; 95% CI 8.55-51.43). 
 
Repeated surgery and permanent stoma 
In the S+ group, 86% (120/139 patients) had their stoma closed. In the S- group, 35 patients 
(24%) had a diverting stoma constructed after LAR, 86% (31/35) due to AL. Forty-nine % 
(17/35) of those were closed (P<0.001) compared to closure of S+ (Table 8). 
 
Table 8. Construction and closure of primary/first stoma and permanent stoma 
  
S+ 
n=139 
 
 
S- 
n=148 
 
p-value 
 
Primary stoma at LAR 
 
 
139 
 
0 
 
 
First stoma not at LAR 
 
 
0 
 
35(24) 
 
 
Closure of primary/first 
stoma  
 
 
120(86) 
 
17(49) 
 
<0.001
1 
 
Secondary stoma 
 
 
4(3) 
 
2(1) 
 
 
 
Closure of secondary 
stoma 
 
 
0 
 
0 
 
 
Permanent stoma 
 
 
23(17) 
 
20(14) 
 
0.472
1 
Percentages shown in brackets. 
1 Pearson’s X2 test 
 
In total, 137 patients in the cohort underwent stoma closure. In patients with AL where the 
diverting stoma were reversed (n=37), 5 patients required a secondary permanent stoma 
(14%). In addition, in patients without a diagnosed anastomotic leakage at the time of 
reversal (n=100), only one patient (1%) required a secondary permanent stoma (due to an AL 
diagnosed 2 years later). 
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Time from construction to stoma closure was significantly shorter in S+; 188 (16-992) days 
in median, compared to 271 (123-482) days in S- (P=0.027). In patients with AL, time from 
construction to closure was similar between the groups (S+ 268 (137-814), S- 276 (151-482), 
days in median). 
The median number of further operations including stoma closure was 1 (range 0-2) in the S+ 
group compared with 0 (0-3) in the S- group, P<0.001. 
 
Type of permanent stoma 
Sixty-seven % (29/43) of the permanent stomas were loop ileostomies (Figure 18). In S+, 
87% were loop ileostomies compared with 45% in S- (P=0.012). Two patients in S+ had an 
end sigmoideostomy compared to eight patients in S- (P=0.105). 
AL was the major cause for a permanent stoma in both groups (S+ 74% and S- 85%; P=NS).  
 
Figure 18. Type of permanent stoma 
 
1
 Pearson’s X2 test 
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PAPER III 
Demography and preoperative data 
A total of 351 patients were included; 219 in the HS-group (70 patients with a small bowel 
resection, 149 without) and 132 in the S-group.  
There were no differences between groups regarding gender, age, BMI, ASA classification or 
previous abdominal surgery (Table 9). 
Colorectal cancer and inflammatory bowel disease were the main reasons for having a 
diverting loop ileostomy, 55% and 25%, respectively, with no difference between the groups. 
 
 
Table 9. Patients’ characteristics 
 
Type of anastomosis 
 
Hand-sewn (HS) 
n=219 
 
 
Stapled (S) 
n=132 
 
p-value 
 
Gender (M/F, (%)) 
 
 
126/93 (58/42) 
 
76/56 (58/42) 
 
0.994
1 
Age (median) 
 
58 58 0.536
2 
ASA (median, (range)) 
 
2(1-4) 2(1-3) 0.289
2 
BMI (median, (range)) 
 
25(14-39) 25(16-38) 0.831
2 
Previous abdominal 
surgery (%) 
 
118(54) 70(53) 0.877
1 
1
 Pearson’s X2 test, 2 t-test  
 
Operative data 
Operation time was in median (range), 80 (20-470) minutes in the HS-group compared to 70 
(25-335) in the S-group, P=0.015.  
A surgical registrar was the operating surgeon in 117 (33%) of the closure procedures and a 
consultant colorectal surgeon performed 91 (26%) operations. 
 
Postoperative data 
SBO occurred among 44 patients (13%) in the entire cohort of which 16 patients (36%) 
required reoperation. In the HS-group, the frequency of SBO was 16% compared with 8% in 
the S-group, P=0.029 (univariate analysis). In a multivariate analysis, there was a 56% risk 
reduction for SBO if a stapled anastomosis was constructed (OR 0.44; 95% CI 0.21-0.93).  
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There was no difference in the number of reoperations due to SBO between the groups 
(P=0.309) or in the frequency of AL (seven patients in the HS-group vs. three patients in the 
S-group, P=0.614). 
LOS was significantly longer in the HS-group (median 5.5 (range 1-194) days) compared 
with the S-group (median 4 (range 1-72) days; P<0.001). 
 
PAPER IV 
Demography, preoperative and operative data 
A total of 29 patients were randomised and included in the study, 13 patients in the ONS-
group and 16 patients in the PEG-group. The median time from randomisation to surgery was 
five weeks (range 1-11) and three weeks (range 2-11) in the ONS and PEG groups 
respectively, P=0.142. 
All of the patients were classified as SGA-A (i.e. not malnourished). The groups were 
comparable regarding demography, co-morbidity, neoadjuvant treatment, tumour stage and 
type of surgical procedure (Table 10). 
During the time period from inclusion to the day before surgery, the ONS-group had a higher 
preoperative caloric intake compared to the PEG-group (median 34 (24-65) vs. 26 (14-37) 
kcal/kg/day, P=0.005) and significantly more patients in the ONS-group reached their RDI; 
77% versus 19% in the PEG-group (P=0.003). 
Grade of bowel cleansing differed between the groups. In the ascending colon, seven patients 
in the ONS-group compared with 13 patients in the PEG-group had an empty bowel 
(P=0.015). In the transverse and the descending colon, six patients in the ONS group 
compared with 15 patients in the PEG group had an empty bowel (P=0.003). No difference 
was seen in the degree of cleansing of the sigmoid and rectum, (P=0.444) and spillage of 
faecal content when constructing the anastomosis (P=0.481). 
 
Postoperative data 
Postoperative morbidity was comparable, 23% (three patients) in the ONS-group and 38% 
(six patients) in the PEG-group, P=0.454. 
Infectious morbidity in the form of urinary tract infection was found in two patients in the 
ONS group and four patients in PEG-group (P=0.663). 
Frequency of surgical morbidity (i.e. some patients had more than one complication) was 8% 
in the ONS-group and 31% in the PEG-group (P=0.183) (see Figure 19). 
There was no difference in the recovery items measured. 
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Table 10. Patient characteristics and preoperative data 
  
ONS 
n=13 
 
 
PEG 
n=16 
 
p-value 
 
Age: years ± SD 
 
66.2 ± 9.2 
 
62.4 ± 9.6 
 
0.292
4 
 
Gender: Male/Female 8/5 10/6 0.958
1 
 
BMI ± SD 24.9 ± 4.2 26.6 ± 3.4 0.091
4 
 
SGA-A: n (%) 13(100) 16(100)  
ASA   
 
1.000
3 
 
ASA 1: n 1 1  
ASA 2: n 12 14  
ASA 3: n 0 1  
 
Smoker: n 
 
0 
 
0 
 
 
Comorbidity: n 
   
1.000
3 
 
Heart failure 
 
0 
 
0 
 
Hypertension 6 7  
Pulmonary dysfunction 0 0  
Diabetes 0 0  
Cortisone treatment 0 0  
 
Neoadjuvant treatment: n 
 
10 
 
13 
 
1.000
3 
Radiotherapy: n 9 12  
Chemo/Radiotherapy: n 1 1  
 
Stage: n 
   
0.207
3 
T-stage I 5 6  
T-stage II  5 2  
T-stage III  3 8  
T-stage IV  0 0  
 
Tumor level: median 
(range) 
 
10(3-18) 
 
9(6-15) 
 
0.707
4 
 
Procedure: n 
   
0.553
3 
LAR with loop ileostomy 7 12  
APR 2 2  
AR 4 2  
Stoma: n (%) 9(69) 14(88) 0.228
3 
Laparoscopic/open 1/12 3/13 0.606
3 
 
1
 Pearson’s X2 test, 3 Fisher’s exact test, 4 Wilcoxon rank sum test 
 
Nutritional and physiological data 
Patient in the ONS-group lost less in weight (mean -1.6 kg vs. -4.6 kg; P=0.028) compared 
with the PEG-group, from randomisation to four weeks after surgery. 
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In the ONS-group, patients gained 1.9% in body fat, from randomisation until three days after 
surgery (P=0.041), while the PEG-group remained unchanged. Regarding subcutaneous fat, 
the PEG-group had a significant decrease, -1.6 mm from randomisation to surgery (P=0.019), 
whereas the ONS group gained 0.5 mm during the same period. 
There were no other significant differences in nutritional and physiological measurements or 
in quality of life between the groups. 
 
Figure 19. Surgical morbidity 
 
3
 Fisher’s exact test 
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DISCUSSION 
 
 
The data from the current thesis suggest that morbidity after low anterior resection, among 
patients treated within an ERAS program, seems not to be affected by a diverting loop 
ileostomy. Even though the number of patients requiring an acute relaparotomy (<30 days 
from LAR) for anastomotic leakage was higher in those not diverted, the overall frequency of 
acute relaparotomy and length of hospital stay was not influenced. Moreover, patients 
without a loop ileostomy at LAR had a faster postoperative recovery. In the longer term, 
those diverted at LAR had a longer total LOS and a higher risk for repeated surgery, without 
any differences in risk of late AL, late readmissions, oncological outcome or permanent 
stoma. 
When closing a diverting loop ileostomy, a stapled anastomosis was associated with a shorter 
operation time, LOS and a lower rate of postoperative small bowel obstruction. 
Finally, we have demonstrated that oral nutritional supplements in combination with rectal 
enema before rectal cancer surgery might be a safe alternative (in terms of surgical 
complications) to mechanical bowel preparation and may, in addition, improve patients’ 
nutritional status. 
With improved oncological outcomes after rectal cancer surgery, more attention has been 
given to other aspects of postoperative outcome. Despite recent advances and attempts to 
optimise perioperative care, both short and long-term morbidity after low anterior resection is 
considerable.
2, 81, 85, 94, 123
 
Anastomotic leakage, a severe surgical complication after LAR, increases early postoperative 
mortality,
102
 other morbidity,
102
 bowel dysfunction
103
 and the risk for a permanent stoma.
94
 In 
addition, oncological outcome has been suggested to be worse in patients suffering from 
AL.
105
  
In 2007, a randomised multicentre controlled trial showed a reduction in clinical AL from 
28% to 10% and a lower rate of relaparotomy for leakage if a diverting stoma was 
constructed at LAR.
35
 Thereafter, several meta-analyses have confirmed similar results.
36-39
 
As a consequence, nearly all patients operated on for LAR in Sweden are currently being 
diverted.
2
 However, despite the increased use of loop ileostomy, no dramatic change in rate 
of AL has been found in Sweden or other European countries.
2, 99
 
Although a loop ileostomy is constructed in order to reduce the risk of AL, the morbidity 
associated with this diversion must be acknowledged when considering the overall morbidity 
after LAR. Nearly half of the diverted patients have some kind of complication associated 
with the stoma, where high stoma flow is common and may require readmission in some 
cases.
69, 90
 Moreover, the risk for small bowel obstruction is significant after stoma reversal 
and sometimes surgery is required to resolve this condition.
64
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Another intervention to reduce morbidity after LAR, apart from diversion at primary surgery, 
is the introduction of ERAS pathways.
152
 This evidence-based perioperative care program has 
been widely adopted due to its enhancement of postoperative outcome after colorectal 
surgery.
154, 155
 The advantages have been found mainly in overall morbidity, while surgical 
morbidity has not been convincingly improved.
228
 In addition, it has been shown that a higher 
compliance with the ERAS elements (>70%) correlates with an improved postoperative 
outcome, reduced postoperative morbidity
78, 158
 and even five-year cancer specific survival in 
colorectal cancer.
229
 Previous reports on diverting stomas and AL are based on data from 
traditional perioperative care settings.
35, 36
 A diverting stoma might interfere with certain 
postoperative care elements such as intravenous infusions (due to high stoma flow), 
mobilisation and early oral feeding and thereby worsen the compliance to postoperative 
ERAS items.  
A diverting stoma in LAR among patients treated within an ERAS programme was evaluated 
regarding short (Paper I) and long-term (Paper II) morbidity.  
The rate of overall short-term morbidity and clinical AL in Paper I was somewhat higher 
compared with some previous studies
83, 84
 which may be due to several different factors. 
Previous reports focus mainly on AL whereas overall morbidity is only rarely reported. In our 
study, all morbidity was included and classified according to Clavien-Dindo
153
 in 
combination with a wide definition of AL. Previous studies have shown that surgeons are 
prone to underreport postoperative morbidity.
77
 Therefore, in the current studies, information 
was prospectively collected and recorded by a trained study nurse. Furthermore, only LAR 
was included and not high anterior resections (PME), which are known to have a lower rate 
of AL.
42
 Finally, nearly 80% of the patients had preoperative radiotherapy, which is higher 
than in most previously published reports and a known risk factor for AL
107
 and worse 
functional outcome.
85
  
Avoiding fluid overload has been demonstrated to be an independent predictor of improved 
outcome after colorectal surgery.
78, 158
 In Paper I, patients without a stoma had a larger 
volume of intravenous infusions on the day of surgery (compliance with ERAS <3.5 litres on 
the day of surgery) and in general, a lower compliance with the ERAS protocol compared 
with those diverted (probably due to higher ERAS compliance over time). Nevertheless, 
short-term morbidity was 53% for patients with a stoma and 43% in those without. Yet, this 
apparent difference was not statistically significant, and neither was the difference in 
infectious complications (19% vs. 11%). It could be speculated that a higher pre and 
perioperative compliance with ERAS in the non-diverted group may have reduced 
complications further, thereby resulting in a significant difference.  
After surgery, postoperative overall compliance to ERAS (measured on the first day after 
surgery) did not differ between the groups. However, patients without stomas were mobilised 
and free from intravenous infusions earlier. 
The number of patients with a clinical AL, both within and after 30 days from surgery, did 
not differ between those with and without a diverting stoma at LAR. This is in contrast to a 
previous RCT
35
 and meta-analyses (ranging from 648 to 11,429 patients included),
36-39
 but in 
similarity with some other prospectively and retrospectively performed cohort studies.
121, 122
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Yet, some previous cohort studies have a risk of selection bias with high-risk patients among 
those diverted, which could have influenced the results.  
However, more recent reports have showed similar results as those in Paper I. Bakker et al. 
compared 2 585 patients with or without a diverting stoma or end colostomy in rectal cancer 
surgery and found a lower rate of mortality, morbidity and LOS in those without a stoma. 
However, the rate of AL was significantly higher, 12% vs. 9%.
117
 The second study by 
Snijders et al. compared patients undergoing anterior resection (N=3104) in hospitals with 
high stoma rates (88%) versus centres with low stoma rates (26%). Baseline characteristics 
were comparable between the groups and there were no differences in early AL or mortality. 
The authors concluded that the main reason for stoma construction was the strategic approach 
of the hospital rather than a systematic bias where centres with higher stoma rates had more 
high-risk patients compared with centres with lower stoma rates. In this study, it appeared 
that hospitals with low stoma rates were better at selecting high-risk patients
230
 in which 
deviation was deemed necessary. Finally, Shiomi et al. used a grading system for selection 
bias to match 936 patients with or without a stoma. The rate of AL was similar between the 
groups (11% vs. 16%, with and without primary diversion, respectively) but frequency of 
relaparotomy due to AL was higher in those not diverted, also in accordance with our 
findings.
118
 This could be explained by a more severe consequence of the leakage in the 
absence of a stoma or simply that a stoma remains necessary in the treatment of most patients 
following AL. However, in Paper I, the overall rate of acute relaparotomy and frequency of 
interventions due to AL, grade B and C-complications included, did not differ. 
Neither in Paper I, nor in previously mentioned RCTs or meta-analyses, was a diverting 
stoma associated with decreased mortality, other morbidity, LOS or readmissions within 30 
days after surgery.
35-39
 In contrast, in some studies, diverted patients had a longer LOS, 
regardless of whether stoma closure was included or not.
35
 
The impact of a loop ileostomy on long-term morbidity after LAR has been less explored. In 
previous reports, a diverting stoma has not been found to reduce the rate of late leakage,
128
 
permanent stomas
94
 or oncological outcome,
106
 similar to the findings in Paper II.  
In addition to the outcomes reported in Paper II, QoL, incisional and parastomal hernias as 
well as functional outcome should be included in long-term morbidity. Approximately 40% 
have been reported to suffer from severe LARS more than two years after surgery
85
 without 
any known correlation with diversion at LAR,
124
 where major LARS has been suggested to 
correlate with worse QoL.
86
 This is important to keep in mind since sphincter-preserving 
procedures have become the most common surgical approach for rectal cancer.
2
  
Of all patients with AL, in Paper II, 43% ended up with a permanent stoma, irrespectively of 
primary diversion or early or late leakage. In comparison, only four percent of patients 
without AL had a permanent stoma at the end of the follow-up.  
Among the patients with AL who underwent subsequent stoma closure, 14% required a 
secondary stoma compared with 1% of those without an AL. 
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Most of the permanent stomas, among those primarily diverted at LAR, were loop 
ileostomas. In contrast, nearly 50% of the patients that were diverted later on received a loop 
ileostomy or an end sigmoideostomy, respectively, as a permanent stoma.  
An end sigmoideostomy has been suggested preferable as a permanent stoma due to 
advantages in stoma handling and less risk of high stoma flow.
94
 Obviously, for those 
primarily diverted in our cohort, the loop ileostomy that became permanent was never closed 
compared to those diverted later on where a permanent solution was constructed more 
frequently.  
In Paper III, a stapled anastomosis for closure of a loop ileostomy was associated with a 50% 
reduction in the risk of SBO compared with a hand-sewn anastomosis. Moreover, operation 
time and LOS was shorter in this group. These findings are in agreement with two published 
RCTs
74, 75
 and two meta-analyses.
71, 73
 The largest RCT by Löffler et al. (N=328), showed 
SBO in 10% vs. 17% (stapled vs. hand-sewn) and a longer operating time in the hand-sewn 
group 
72
. However, the difference in SBO was not statistically significant between the groups. 
In a stapled anastomosis, the new intestinal lumen is wider compared with a hand-sewn 
anastomosis and the intestines need to be more extensively dissected in order to enable 
correct positioning of the staple instrument. This might explain the decreased frequency of 
SBO following this procedure. Thus, some of the previous studies included a mixed study-
population containing both rectal cancer and IBD patients and the hand-sewn anastomosis 
were performed in different ways.
68, 71, 73
 Even though end-to-end anastomosis is the most 
common, side-to-side and end-to-side have been used. This might blur the results, since 
patients with different diagnoses and different types of hand-sewn anastomoses are not 
always comparable. Nonetheless, in Paper III, the influence of the underlying diagnosis in 
patients having a loop ileostomy (i.e. rectal cancer or IBD) was evaluated in a multivariate 
analysis and was not found to be a predictor for postoperative SBO. 
Malnutrition and weight loss prior to surgery is associated with a worse postoperative 
outcome.
191, 193
 Nearly 50% of the patients awaiting abdominal surgery for malignancy suffer 
from preoperative weight loss.
190
 Despite this, there are no general recommendations or 
guidelines on how to approach this problem in rectal cancer surgery. Previous reports differ 
in administration of nutrition, type of nutritional supplement and duration of treatment and 
most often only patients with severe malnutrition are included.
191, 193
 
The use of mechanical bowel preparation in colorectal surgery might increase the risk of fluid 
shift and electrolyte imbalance and also prolongs preoperative fasting.
158, 178
  
The hypothesis in Paper IV was that oral nutritional supplements before rectal cancer surgery 
would improve the nutritional status of the patients. Thus, the risk for a catabolic state at the 
time of surgery would decrease and the stress response and degree of insulin resistance would 
be attenuated. In addition, due to its residue-free constitution, the bowel would be clean 
enough for rectal cancer surgery. Thereby, traditional MBP with PEG, with its potential side 
effects, could be avoided.  
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Even though only well-nourished patients were included, an improvement in patients’ 
nutritional status was observed in the interventional arm, in which patients gained in percent 
body fat and lost less weight.   
To our knowledge, there is only one previously published study showing the same correlation 
between preoperative treatment with ONS and weight loss. This RCT, by Smedley et al., 
found that perioperative ONS reduced weight loss and minor complications after colorectal 
surgery.
200
 In Paper IV, postoperative ONS was given according to the ERAS protocol.
149
 
The higher rates in both overall and surgical morbidity observed in the PEG-group did not 
reach statistical significance. However, the study was underpowered for the detection of any 
difference in this outcome.  
Although the colon was less clean in those treated with ONS, the distal colon and rectum was 
similarly clean compared with the PEG-group, in accordance with previous findings in 
patients randomised to ONS or PEG as preparation before colonoscopy.
231
 In addition, there 
was no difference in spillage when the bowel was opened. In fact, all three patients with AL 
had had traditional bowel cleansing. Undeniably, larger studies are warranted to confirm 
these novel findings and to detect a potential effect on postoperative outcome. However, 
ONS might be an option to avoid traditional MBP and thereby hitting two birds with one 
stone, considering the additional benefits with regards to nutritional outcome. 
In summary, clinical anastomotic leakage, or at least its initial consequences, might be 
reduced by a diverting loop ileostomy at low anterior resection. However, early mortality, 
other morbidity and LOS are not influenced. Moreover, long-term morbidity, including 
oncological outcome and the risk of a permanent stoma are comparable between those 
primarily diverted and patients diverted due to anastomotic leakage. Due to this, and bearing 
in mind the significant stoma-related morbidity, current practice in which most patients are 
diverted during LAR, may have to be reconsidered. A more selective approach, with a 
diversion in high-risk patients and in those where the clinical consequences of an AL could 
postpone subsequent adjuvant treatment, may be a possible new strategy. Thus, future studies 
should focus on the identification of patients with a high risk of leakage, thereby leading to 
improved clinical decision-making and better patient outcomes.  
In patients who are diverted, a stapled anastomosis might be preferred during the closure 
procedure, to diminish the risk of postoperative SBO. However, larger RCTs including only 
patients with rectal cancer and end-to-end anastomosis are needed to confirm this result. 
Finally, adherence to the ERAS protocol decreases the overall morbidity after rectal cancer 
surgery. Thus, to enhance all patients’ nutritional status (even in those without severe 
malnutrition preoperatively) the use of a residue free regimen seems to provide an alternative 
to traditional bowel cleansing before surgery, which might further improve postoperative 
outcome. 
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General methodological aspects and limitations of the thesis 
Randomised controlled trials have many advantages. However, even RCTs can suffer from 
selection and information bias and unknown confounders, the three major limitations in a 
prospective or retrospective cohort study. 
Studies examining different types of surgical procedure are made more difficult as it is not 
possible to blind the surgeon. Patients selected may be more suitable for inclusion and 
sometimes healthier persons are more prone to participate. Therefore, a well-conducted non-
randomised cohort study should not be underestimated. If prospectively performed, the risk 
of information bias is reduced and a large number of variables can be collected to diminish 
the risk of confounding. In addition, the case-mix in a large cohort study, including all 
consecutive patients in a certain group, such as those undergoing rectal cancer surgery, may 
better represent the patients that are to be studied. Depending on the trial, all patients can be 
included and followed for a long time. 
A retrospective cohort study has a higher risk for bias but can be performed quicker. In case 
of well defined exposure and outcome measures and if a large cohort of patients are 
evaluated, conclusions can still be made. Moreover, a RCT may not always be ethical and on 
those occasions, a non-randomised cohort study could be the only option available to the 
researcher. 
 
Paper I 
Due to the change in practice regarding primary diversion after 2007, the two surgical 
procedures where unequally distributed between two different time-periods (2002-2006 and 
2007-2011). Thus, there is a risk that patients with diversion in the earlier time-period may 
have had a higher risk for leakage and vice versa. However, only 15% and 9% of the patients 
differed in strategy within the time-periods and when these 36 cases were excluded from the 
analysis, the results remained the same. Moreover, all calculations (comparison of 
demography, operative findings and postoperative morbidity and recovery) were performed 
between the two time-periods as well. In concordance with the results presented in Paper I, 
some differences regarding preoperative chemotherapy, type of anastomosis, operation time 
and ERAS compliance were found when comparing the two time-periods.  
Certainly, there may still be unknown confounders in the cohort, but the known confounders 
have been adjusted for in a multivariate analysis (both between stoma and no stoma and the 
two time-periods). Moreover, the risk of selection bias regarding surgical procedure is low 
since all patients with a complete TME were included and the institutional indications for 
TME were the same during the study period. Furthermore, the data were prospectively 
collected and the participating surgical staff were the same during the entire study-period.  
The high morbidity observed in the study and the impact of the ERAS programme should be 
discussed. The ERAS database gives the opportunity to compare several prospectively 
registered outcome measures regarding postoperative morbidity and recovery. As mentioned, 
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all patients with a complete TME were consecutively included and a study nurse performed 
the collection of data, including the recording of all complications. The majority of the 
patients had had preoperative RT and the definition of AL was wide. Nevertheless, the 
morbidity rate and the frequency of AL are comparable to previous studies, in which patients 
undergoing low as well as high anterior resection (known to have a lower rate of 
postoperative complications compared to a complete TME) were included.   
 
Paper II 
Systematic collection of data regarding functional outcome, urogenital and bowel 
dysfunction, quality of life, incisional and parastomal hernias was not performed. The risk of 
recall and information bias, from both patients and surgeons, and a select group of patients 
willing to answer questions regarding QoL make some of these data difficult to evaluate 
retrospectively. Nevertheless, one may assume that several of the patients in Paper II who had 
a permanent stoma due to AL, also had impaired bowel function.  
There is a risk of missing data from patients referred to another emergency hospital than Ersta 
and for those who had their follow-up at another centre. Still, the majority (94%) of the 
patients (death excluded) had a complete three-year follow-up at our institution. Moreover, 
any complication/readmission revealed from another hospital was included in our analysis 
and most of the patients initially readmitted to a different hospital because of complications 
were sent to Ersta the following day. 
 
Paper III 
A multicentre RCT may have been preferable, including only patients operated on for LAR 
with a loop ileostomy to ensure enhanced external validity. However, compared with other 
trials on the subject, this retrospective cohort study is large (N=351) with well-defined 
outcome measures (SBO and AL) and three different Swedish hospitals were included.  
The study was planned in 2007, due to a high observed complication rate after the increased 
use of diverting stomas. Since approximately 50% of the patients with LAR had a diversion 
between the study-period 1999-2006, all patients with stoma closure were included in order 
to gain study power. However, in 55% of the included patients, LAR was the primary 
procedure and in a multivariate analysis, the underlying diagnosis did not influence the rate of 
postoperative SBO.  
Information regarding perioperative bleeding and type of incision (parastomal or laparotomy) 
are missing. These two variables could have had impact on postoperative morbidity. 
However, stoma closure is most often performed using parastomal access with only a small 
amount of blood loss. 
It is sometimes difficult to separate normal postoperative paralysis from SBO. Therefore, the 
rate of SBO observed in the study might be somewhat high. However, the definition of SBO 
used in the study was both clinical and radiological. 
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Paper IV 
Although the study was designed as an RCT, the cohort was small. The duration of the 
inclusion period was long, the patients included had low co-morbidity and were well 
nourished, representing only a fraction of the patients treated for rectal cancer at our 
institution. Despite these limitations, the calculated required sample size with 18 
patients/group was almost reached and a difference in the primary outcome (nutritional 
status) was found. Moreover, compliance with the study protocol (registration of caloric 
intake, step-calculation, outcome variables measured) among the included patients was high 
and there were few missing data. 
Certainly, the current data indicating a worse outcome in the PEG-group needs to be 
confirmed in a larger study. However, questions have arisen from the current trial regarding 
the value of preoperative treatment of all patients with ONS before rectal cancer surgery and 
whether mechanical bowel preparation may be avoided before small bowel diversion in these 
patients. 
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CONCLUSIONS 
 
 
Overall conclusion 
Morbidity after low anterior resection for rectal cancer is high, even in patients with a 
diverting stoma and perioperative treatment according to the ERAS protocol.  
 
Specific conclusions 
Clinical anastomotic leakage and other morbidity after low anterior resection for rectal cancer 
seems not to be reduced by a diverting loop ileostomy among patients treated according to an 
ERAS protocol. 
A diverting loop ileostomy at low anterior resection decreases the need of acute relaparotomy 
due to anastomotic leakage but does not affect the total rate of acute reinterventions or length 
of hospital stay. 
Among patients treated within an ERAS programme, postoperative recovery after low 
anterior resection seems to be slower in patients with a diverting loop ileostomy.   
Long-term morbidity after low anterior resection (including readmissions, late anastomotic 
leakage, risk of permanent stoma and oncological outcome) seems not to be reduced by a 
diverting stoma at primary surgery. Instead, total length of hospital stay and number of 
surgical procedures required is higher in diverted patients. 
After closure of a diverting loop ileostomy, occurrence of postoperative small bowel 
obstruction, operation time and length of hospital stay may be reduced by a stapled, 
compared with hand-sewn, anastomosis. 
A residue-free diet before rectal cancer surgery using oral nutritional supplements in 
combination with rectal enema may be an alternative to traditional mechanical bowel 
preparation. 
Oral nutritional supplements before rectal cancer surgery seem to improve patients’ 
nutritional status and reduce weight loss after surgery. 
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FUTURE PERSPECTIVES 
 
 
Recent published data suggest a more selective approach towards a diverting stoma in low 
anterior resection for rectal cancer.
79, 133, 230, 232
 In order to change existing clinical protocols 
to a selective approach, it is important to re-evaluate the effect of a stoma on both short and 
long-term morbidity. It is also important to find new perioperative strategies for the 
prevention of AL. Identifying which patients who are at higher risk of AL and therefore 
require a diversion at LAR may be a key for improved postoperative outcome. Future studies 
should therefore focus on the role of a diversion in LAR among patients treated within a 
modern perioperative setting in order to define high-risk patients for AL. An algorithm for the 
risk of AL in individual patients, including all known risk factors, stage of the tumour and 
eventually neoadjuvant and adjuvant treatment, may help in this decision making framework. 
Moreover, new approaches such as ghost stoma or a percutaneous ileostomy in combination 
with early radiology could be an alternative to stoma diversion and may even decrease the 
risk of relaparotomy in case of a leakage. Adjuncts, such as fluorescence angiography with 
near-infra red light technology, might detect impaired micro perfusion. This could contribute 
to the decision regarding where to divide the bowel, where to make the anastomosis and 
thereby, which patients would benefit from a loop ileostomy.  
Furthermore, the effect of intestinal microflora and probiotics on postoperative morbidity, 
including anastomotic dehiscence, is also generally unexplored.  
Few studies have addressed long-term morbidity after LAR in relation to a diverting stoma. 
Even though no current data suggest any benefit of a diversion, larger prospective cohort 
studies are warranted. These studies should also assess bowel dysfunction, quality of life and 
oncological outcome. If future reports confirm that a diversion at LAR do not benefit long-
term outcome and morbidity this would add arguments for a selective approach. 
Currently, except in the case of severely malnourished patients, there is no general 
recommendation regarding nutritional supplements before rectal cancer surgery. Further 
larger studies are required to ascertain whether ONS and rectal enema may safely replace 
mechanical bowel preparation before primary diversion at rectal cancer surgery and if the 
observed enhancement in patient nutritional status further influences postoperative morbidity 
and outcomes.  
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SAMMANFATTNING FÖR ICKE-KIRURGER 
 
 
Till mamma 
 
Årligen drabbas nästan 2000 personer i Sverige av ändtarmscancer, den sjunde vanligaste 
cancerformen för både kvinnor och män. Trots att sjukdomen blivit allt vanligare, överlever 
idag nästan 65 % - en avsevärd förbättring sett över en 50-årsperiod.  
I dagsläget är kirurgi det som kan bota, men dessvärre är en operation inte ofarlig. En av de 
operationsmetoder som används innebär att ungefär 40 % får komplikationer direkt efteråt 
och en hög andel får även bestående men. Svårigheter med avföringen, urinen och det 
sexuella är vanligt, och nästan en av fem riskerar att få en livslång påse på magen, s.k. stomi.  
En av de mest fruktade komplikationerna är anastomosläckage, att den nya tarmskarven 
läcker. Detta innebär i sig en ökad risk för tidig död, andra komplikationer, dålig 
tarmfunktion och att man får en livslång stomi. 
En tillfällig stomi, samtidigt som själva ändtarmsoperationen, tros minska risken för läckage 
från den nya tarmskarven. I Sverige får därför en stor andel av de som opereras samtidigt en 
tillfällig stomi. Några månader efter operationen är tanken att den ska stoppas tillbaka ner i 
buken, s.k. stominedläggning. 
Trots denna åtgärd får fortfarande många anastomosläckage. Dessutom riskerar stomin att ge 
ytterligare sjukvårdskrävande besvär, både genom att ha den och när man ska lägga ner den. 
En riskfaktor för komplikationer efter operation är viktnedgång och näringsbrist. Nästan 50 % 
av de patienter som ska genomgå ändtarmskirurgi har gått ner i vikt innan operationen. Trots 
detta finns det inte något allmän strategi för hur man ska hantera problemet. 
Att vårdas enligt ett speciellt vårdprogram, ERAS (Enhanced Recovery After Surgery), där 
man som patient inte ska fasta i onödan, vara ordentligt smärtlindrad, röra på sig och äta så 
fort som möjligt efter operationen har visat sig minska komplikationerna efter kirurgi. 
Däremot kan det praktiskt vara svårt att genomföra alla åtgärder som innefattas av ett ERAS-
program, varför många sjukhus väljer att avstå helt eller bara använda delar utav programmet. 
I detta avhandlingsarbete, uppdelat på fyra delarbeten, har nyttan av den tillfälliga stomin vid 
ändtarmscancerkirurgi utvärderats hos patienter som behandlats enligt vårdprogrammet 
ERAS. Dessutom har patienter som fått näringsdrycker innan ändtarmscancerkirurgi 
undersökts avseende komplikationer efter operationen och om denna metod även rengjort 
tjock och ändtarmen tillräckligt. 
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Arbete I 
Gör den tillfälliga stomin vid operation av ändtarmscancer nytta om patienterna också 
behandlas enligt vårdprogrammet ERAS? 
Alla 287 patienter som genomgått en viss operation för ändtarmscancer på Ersta sjukhus, 
mellan år 2002-2011, kontrollerades. Knappt hälften av dessa hade opererats med en tillfällig 
stomi och drygt hälften utan. Dessa två grupper jämfördes. 
Det var ingen skillnad i antal eller typ av komplikationer efter ändtarmskirurgin mellan 
grupperna. Fler patienter som inte fått en stomi blev akutopererade för att tarmskarven läckte, 
men sett på antalet akutoperationer - oavsett orsak - så var det ingen skillnad. 
Gruppen av patienter utan stomi återhämtade sig snabbare även om den faktiska tiden på 
sjukhus var lika.  
 
Arbete II 
Påverkar en tillfällig stomi vid ändtarmscancerkirurgi komplikationerna på lång sikt? 
Här undersökte vi samma patienter som i arbete I, men jämförde grupperna avseende besvär 
som uppstått mer än 30 dagar fram till 3 år efter operationen.  
Andelen patienter som fått läggas in på sjukhus igen, under denna tid, fått läckage från 
tarmskarven som hittats senare, fått tillbaka sin cancersjukdom eller dött i densamma var lika 
mellan grupperna. Det var inte heller någon skillnad i hur många som fått en livslång stomi. 
Däremot var antalet dagar på sjukhus, totalt sett under denna treårsperiod, fler hos de som fått 
stomi vid ändtarmsoperationen. 
 
Arbete III 
Är en tarmskarvsmetod bättre än en annan vid nedläggning av den tillfälliga stomin? 
Vi undersökte 351 patienter som opererat tillbaka sin tillfälliga stomi vid tre olika svenska 
sjukhus - Uppsala, Huddinge och Karlstad. En del av dem hade fått sin nya tarmskarv 
handsydd och en del hade fått en staplad (häftad) tarmskarv.  
Hos de som fått en staplad tarmskarv gick operationen fortare (10 minuter), hälften så många 
fick tarmvred (16 % jämfört med 8 %) och de kunde gå hem 1,5 dag tidigare från sjukhuset. 
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Arbete IV 
Kan näringsdrycker innan operation för ändtarmscancer ersätta laxering för rengöring av 
tarmen och klarar sig de patienter som fått detta bättre efteråt? 
Tjugonio patienter som skulle genomgå operation för ändtarmscancer lottades till att få 
näringsdrycker innan kirurgi (ca 4-6 veckor) eller äta som vanligt, efter eget bevåg, och 
dagen innan operation få dricka 4 liter tarmlaxering (standard i Sverige). 
Vid lottningen till behandlingsgrupperna, dagen innan operationen, tre dagar och fyra veckor 
efter operationen gjordes undersökningar för att mäta patienternas näringstillstånd och fysiska 
förmåga. 
Hos de patienter som fått näringsdrycker var tjocktarmen sämre rengjord men ändtarmen lika 
bra rengjord som hos de som fått tarmlaxering. Andelen komplikationer efter operationen var 
också lika. Däremot hade de som fått näringsdrycker lagt på sig mer underhudsfett fram till 
kirurgin och gått ner mindre i vikt, från lottningen till fyra veckor efter operationen. 
Utifrån dessa fyra delarbeten blir slutsatsen att andelen läckage efter ändtarmscancerkirurgi 
fortsatt är många och besvären, såväl på kort som på lång sikt, tycks inte alltid påverkas av en 
tillfällig stomi. Dessutom tillkommer än mer komplikationer med själva stomin. Det finns 
därför skäl att ifrågasätta regeln att alla i Sverige, som genomgår en viss typ av 
ändtarmscancerkirurgi, samtidigt ska ha en tillfällig stomi. Att innan operationen väga 
argumenten för och emot hos den enskilde individen, i hopp om att hitta den grupp patienter 
som det gagnar mest, är ett möjligt framtida scenario. Vidare, har man väl fått en stomi är en 
staplad tarmskarv vid nedläggningsförfarandet att föredra. 
Till sist, näringsdrycker innan ändtarmscancerkirurgi kan vara ett alternativ till tarmlaxering 
och samtidigt göra patienterna bättre förberedda, rent näringsmässigt, inför och efter kirurgi.  
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